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                                                  Abstract 
 
Non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancer and has a 5 
year survival rate of just 15%. Recently, tyrosine kinase inhibitors (TKIs) have 
been found to give dramatic therapeutic benefit to some patients increasing both 
their overall survival and quality of life compared with the more traditional and 
aggressive platinum-based chemotherapy. Subsequently, it was shown that EGFR 
and KRAS mutations act as biomarkers in predicting of patient response or lack 
thereof, respectively to TKIs.  
As such, the establishment of a clinically relevant assay for the detection of EGFR 
and KRAS mutations would contribute to personalised treatment of NSCLC 
patients to ultimately improve patient outcomes. However, there are many 
limitations and obstacles that limit the sensitivity of current protocols to detect 
these biomarkers, including the inherent heterogeneous nature of NSCLC tumours 
and the poor quality of genomic DNA due to biopsies being stored formalin-fixed, 
paraffin-embedded (FFPE) specimens.  
This study investigated the use of mineral oil to produce a high yield of quality 
DNA from FFPE NSCLC specimens. Additionally, significant optimisation 
experiments were carried out to find the optimum conditions for efficient 
amplification during PCR thermocycling using DNA derived from these FFPE 
specimens. Subsequently, the use of standard PCR, Co-amplification at lower 
denaturation temperature (COLD) PCR, restriction digest-mediated mutant 
enrichment PCR, single-stranded conformation polymorphism (SSCP) and DNA 
melt curve analysis were investigated as EGFR and KRAS mutation detection 
protocols in NSCLC FFPE specimens.  
Significantly, this study found that the use of mineral oil contributed to the 
extraction of a high yield of quality genomic DNA from the FFPE specimens and 
the use of a high fidelity DNA polymerase enzyme and a PCR buffer with a high 
magnesium concentration were required to produce amplifiable products from the 
FFPE specimens. Subsequently, it was found that both SSCP and DNA melt curve 
analysis could detect putative mutations in EGFR exon 21 and 19.  
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Given that SSCP and DNA melt curve analysis could detect mutations in the 
NSCLC FFPE specimens, these mutation detection protocols were shown to be 
more sensitive than direct sequencing. However, further work is required to 
establish a clinical relevant mutation detection protocol for the routine detection 
of EGFR and KRAS mutations in FFPE NSCLC specimens.  
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1 Chapter 1    General Introduction                                              
& Literature Review 
 
1.1 General Introduction 
Lung cancer is the cause of the highest rate of cancer-associated mortality in the 
world, with 1.38 million deaths worldwide annually (Hirsch, 2009; Lee et al., 
2011). Significantly, it is ranked second, behind only cardiovascular disease, as 
the leading cause of death in New Zealand (NZ) and has accounted for more than 
a quarter of all deaths since the 1990s (Hodgen, Tobias, & Chenung, 2002). 
Compared with European countries and Australia, NZ has a relatively high lung 
cancer incidence and mortality rate, with a growing epidemic among females and 
Maori, as well as lower socioeconomic groups (Blakely, Shaw, Atkinson, 
Cunningham, & Sarfati, 2011; Stevens, Stevens, Kolbe, & Cox, 2008; Sutherland 
& Aitken, 2008). Moreover, while the NZ government has forecasted that overall 
rates of lung cancer will decline over the next several years, the cost associated 
with its prevention and treatment will remain a substantial burden to the health 
system for the foreseeable future (Masago et al., 2008).  
Traditionally, lung cancer is treated with combination platinum-based 
chemotherapy, yet this offers only a modest increase in overall survival while 
adversely affecting the patients’ quality of life (Triano, Deshpande, & Gettinger, 
2010). Accordingly, the response rate to standard platinum-based chemotherapy is 
typically 20-30% with a median survival time of approximately 4 months 
(Mitsudomi, 2010; Pao et al., 2009; Sriram, Larsen, Yang, Bowman, & Fong, 
2011). This minimal disease response shown by 70-80% of patients can partly be 
attributed to the aggressive nature of the disease, and the fact that most patients 
present with an advanced metastatic stage at diagnosis. However, the mechanisms 
that contribute to the poor treatment response are wide-ranging and multi-
factorial.  
Consequently, over the past several years, researchers have suggested many 
genetic, environmental, hormonal and viral factors as risk factors for lung cancer, 
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particularly amongst non-smokers. Whilst there have been many associations 
between risk factors and lung cancer incidence, no dominant risk factor has been 
validated across racial and ethnic groups (Abidoye, Ferguson, & Salgia, 2007; 
Lee, et al., 2011). Indeed, despite tobacco smoking being the predominant risk 
factor, only 10-20% of smokers will develop lung cancer, highlighting the 
multifaceted etiology of the disease (Sriram, et al., 2011; Yano, Haro, Shikada, 
Maruyama, & Maehara, 2011).  
In fact, this is typical of complex disease phenotypes, whereby a single causal 
factor cannot explain the multi-step and complicated process of tumourigenesis 
and lung cancer development. Instead, complex gene-environment interactions are 
implicated in the carcinogenesis of lung cancer, and with the completion of the 
Human Genome Project, there is a better understanding of the molecular origins 
and evolution of the disease (Herbst, Heymach, & Lippman, 2008).  
 
1.2 Biology of Lung Cancer 
Lung cancer, like most cancers, is a conglomeration of diseases, broadly divided 
into two main groups, small-cell lung cancer (SCLC) and non-small-cell lung 
cancer (NSCLC), based on the different tissues of origin from which the disease 
develops (Johnson & Kelley, 1995). SCLC which makes up 10-15% of lung 
cancers is of neural crest origin and generally initially responses well to 
chemotherapy, although reoccurrences are common (C. H. Lin, Yeh, Chang, Hsu, 
& Chang, 2010; Sharma, Bell, & Settleman, 2007). Whereas, NSCLC makes up 
85-90% of reported lung cancers and while it originates from lung epithelial cells, 
there are diverse histological subtypes including adenocarcinoma, 
bronchioalveolar, squamous, anaplastic and large-cell carcinomas (Cataldo, 
Gibbons, Perez-Soler, & Quintas-Cardama, 2011).  
Given that survival with lung cancer is closely associated with tumour stage and 
treatment, therapeutic treatment and prognosis has traditionally depended on the 
histological subtype and stage of cancer, as well as the patient’s general wellbeing 
(Stevens, et al., 2008). Significantly, the most frequent type of histological tumour 
is NSCLC adenocarcinoma, which account for 40% of all cases of lung cancer in 
North America and is the predominant form of the disease in most of the world 
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(Jemal, Siegel, Xu, & Ward, 2010). This subtype has a better prognosis than other 
lung cancers, and with optimal treatment the possibility of a cure is greatest for 
this group of patients (Stevens, et al., 2008).  
As such, significant research has been undertaken to establish treatment regimens 
that offer optimal therapeutic benefit for lung cancer patients. Accordingly, recent 
studies have focused on the unique biology of lung cancer tumourigenesis, in 
attempt to establish the pathogenesis pathways that lead to the development of the 
malignant phenotype (Igbokwe & Lopez-Terrada, 2011). In particular, focus has 
been on understanding the complex and aberrant activation of signalling pathways 
that stimulate that six hallmarks of cancers cells; uncontrolled proliferation, 
evasion of apoptosis, insensitivity to anti-growth signals, sustained angiogenesis, 
tissue invasion and metastasis, self-sufficiency in growth signals (Gazdar, 2010).  
 
1.3 Non-small-cell Lung Cancer 
As NSCLC makes up the majority of lung cancers, it contributes significantly to 
the high mortality rate associated with the disease. NSCLC tumours do not 
respond well to chemotherapy, partly due to the advanced stage at which most 
patients present at diagnosis (John, Liu, & Tsao, 2009). As such, the median 
survival associated with the disease is only 4 to 5 months and a prognosis of 
metastatic NSCLC remains poor, with a 5-year survival of only 5% (Cataldo, et 
al., 2011). 
Indeed, NSCLC is a highly aggressive disease and is present both in smokers and 
non-smokers (Wakelee et al., 2007). NSCLC is relatively asymptomatic in that 
patients often only notice a persistent cough, which is not attributed to suffering 
from the disease. Further, while cigarette smoking remains the most substantial 
contributor to the development of lung cancer, 15% of males and 53% of females, 
which combined accounts for 25% of all lung cancers worldwide, diagnosed with 
the disease are non-smokers, highlight the multi-faceted etiology of the disease 
(Sun, Schiller, & Gazdar, 2007).   
Interestingly, while the rates of tobacco smoking are decreasing in much of the 
Western world, there is no corresponding decline in the number of people 
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diagnosed with NSCLC (Jemal, et al., 2010). There is also an increasing epidemic 
in Japan, where lung cancer has been the leading cause of death since 1998 (Yano, 
et al., 2011). Importantly, the clinical manifestation of NSCLC in non-smokers is 
present disproportionately more in women than men suggesting that there are 
several strong predisposing characteristics, including female sex and being of 
Asian descent that contribute to an individual’s chance of developing the disease 
(Provencio, Garcia-Campelo, Isla, & de Castro, 2009).  
 
1.3.1 Molecular biology of Non-small-cell Lung Cancer 
The development and progression of NSCLC is a multi-step process, 
characterised by the accumulation of multiple genetic and epigenetic lesions, 
which result in aberrant cell regulatory systems and growth-control pathways 
(Choi et al., 2007; Kolch & Pitt, 2010). Specifically, it has been shown that 
NSCLC tumour cells acquire common phenotypes such as the self-sufficiency 
of growth signals and resistance to anti-proliferative and apoptotic signals due 
to these molecular lesions (Mitsudomi, 2010). 
Indeed, over the past couple of decades, the advent of next-generation 
molecular techniques and our ability to sequence entire genomes has uncovered 
the specific genetic alterations that confer uncontrolled proliferation and 
apoptotic resistance in NSCLC tumour cells (Bunn, Soriano, Johnson, & 
Heasley, 2000). This has not only significantly contributed to our 
understanding of the biological mechanisms that underlie tumourigenesis in 
NSCLC, but has also elucidated several key differences in this process in 
smokers and non-smokers (Ramalingam, Owonikoko, & Khuri, 2011). 
Consequently, the evaluation of the pathogenesis and biological differences 
between NSCLC in smokers and non-smokers has contributed to a greater 
understanding of molecular differences which contribute to the development of 
the disease in these two groups. Accordingly, it is now hypothesised that 
NSCLC in smokers and non-smokers should be considered two different 
diseases based on the differences in the molecular lesions that contribute to 
their development (Sun, et al., 2007; Yano, et al., 2011).  
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1.3.2 Somatic Mutations in Non-small-cell Lung Cancer 
Somatic mutations in cellular DNA underlie almost all human cancers (Weir et 
al., 2007). NSCLC is no different, as shown by Lee et al (2010) who sequenced 
the genome of an adenocarcinoma of a former smoker, and identified more 
than 50,000 single nucleotide variants and 530 somatic mutations, with an 
estimated genome-wide somatic mutation rate of 17.1 per megabase.  
While the significance of the vast majority of mutations acquired by NSCLC 
tumours currently remains unknown, research has revealed that a small group 
of genetic lesions are not only necessary for the initial development or 
progression of the disease but also are required for the maintenance of that 
tumour’s survival (Pao, Iafrate, & Su, 2011; Ramalingam, et al., 2011). Not 
surprisingly, these ‘driving’ oncogenic mutations are present in genes that 
encode proteins involved in key cellular pathways, and oncogenic activation of 
these proteins results in aberrant activity, thus contributing to the development 
of the hallmarks of cancer (Hanahan & Weinberg, 2000).   
Specifically, two key proto-oncogenes have been identified in NSCLC, 
whereby the accumulation of a mutation within either of these genes is 
considered an important early step in driving pathogenesis and development of 
tumours (Pao, et al., 2011). These two genes are epidermal growth factor 
receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
(KRAS). Both these genes encode proteins involved in cellular signalling 
pathways that control key characteristics of cellular growth and survival 
(Herbst, et al., 2008; Schubbert, Shannon, & Bollag, 2007). 
 
1.4 Epidermal growth factor receptor (EGFR) 
The epidermal growth factor receptor (EGFR) is one of four receptor tyrosine 
kinases of the ERBB or HER family of receptor kinases (Pao, et al., 2011; 
Sharma, et al., 2007). The EGFR gene is 188,306 base pairs (bp) and encodes a 
transmembrane glycoprotein which acts as a cell surface receptor that is routinely 
expressed in various tissues of epithelial, mesenchymal and neural origin (Zhang, 
Stiegler, Boggon, Kobayashi, & Halmos, 2010). 
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The protein encoded by the EGFR gene is a 170 kilo Daltons (kDa) cell 
membrane receptor, composed of an extracellular cysteine-rich ligand binding 
domain, a single alpha-helix transmembrane domain, and an intracellular domain 
with tyrosine kinase activity in the carboxyl-terminal tail (Figure 1) (Jimeno & 
Hidalgo, 2006; Kosaka et al., 2004; Takeuchi & Ito, 2010).   
The crucial role of EGFR in normal development has been illustrated by a series 
of knockout mice models. Indeed, depending on their genetic background, mice 
without EGFR die between day 11.5 of gestation and day 20 after birth. Further, 
knockout mice show placental defects, lung immaturity, and various abnormalities 
in the bone, brain, heart, and various organs such as gastrointestinal tract, skin, 
hair follicles and eyes (Zhang, et al., 2010).  
 
Figure 1 Schematic diagram showing the structure of the EGFR gene and the protein domains it 
encodes. There are three main domains: extracellular cysteine-rich domain (exons 2-16), 
transmembrane region (exon 17) and the tyrosine kinase domain. The tyrosine kinase domain encoded 
by exons 18 – 24 is magnified out to the right of this picture. The activating mutations are present in 
exon 19 and 21. Adapted from Abidoye et al. (2007) 
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1.4.1 EGFR cellular pathway 
The EGFR cellular pathway was discovered by Stanley Cohen in the 1960s and 
since has become one of the highly characterised cellular pathways (Hanahan 
& Weinberg, 2000).The binding of epidermal growth factor, or another ligand, 
to the extracellular domain of EGFR induces homo-dimerisation or hetero-
dimerisation with other members of ERBB family (Ansari, Palmer, Rea, & 
Hussain, 2009). The formation of these dimers results in conformational 
changes which activate the receptor and induce the tyrosine kinase catalytic 
activity the intracellular tyrosine kinase domain (Pao, et al., 2011). 
Subsequently, this activation leads to auto-phosphorylation of one or more of 
the five tyrosine residues in the carboxyl-terminal tail, producing 
phosphotyrosine sites where adaptor and docking molecules will ultimately 
bind (Jimeno & Hidalgo, 2006). As such, the activation of EGFR ultimately 
leads to the phosphorylation of specific tyrosine residues in key members of 
several intracellular signalling pathways which promote cell proliferation 
and/or survival.  
As shown in Figure 2, important intracellular pathways activated by EGFR 
include the PI3K-AKT-mTOR pathway involved in cell survival processes, and 
the RAS-RAF-MEK-ERK pathway involved in the transcription of molecules 
involved in cell proliferation, transformation and metastasis development 
(Franklin et al., 2010; Herbst, et al., 2008)  
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Figure 2 Schematic diagram showing EGFR and the associated cellular pathways. The PI3K-AKT-
mTOR pathway is involved in cell survival while the RAF-MEK-ERK pathway is involved in cellular 
proliferation. 
 
1.4.2 EGFR dysregulation and carcinogenesis 
Given its pivotal role in cellular growth and development, the dysregulation of 
the EGFR gene or protein was suggested to be involved in carcinogenesis. 
Indeed, this was confirmed in the 1980s, when EGFR was demonstrated to be 
involved in tumourigenesis, and the overexpression of EGFR was shown to be 
associated with advanced stages of disease, resistance to conventional 
treatments and poor prognosis (Bearz, Berretta, Lleshi, & Tirelli, 2011). Since, 
EGFR has been found to be overexpressed in a variety of human malignancies 
including colon, breast, pancreas and NSCLC tumours (Kolch & Pitt, 2010). 
Interestingly, while more than 60% of NSCLC tumours show overexpression 
of EGFR, no overexpression is seen in SCLC (Zhang, et al., 2010).  
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Additionally, not only is the EGFR gene overexpressed in many cancers, but it 
has also been shown that the EGFR and its associated network is frequently 
altered in many cancers (Kolch & Pitt, 2010). This resultant aberrant activity of 
EGFR and the associated downstream signalling pathways have been shown to 
be involved in the development of several hallmarks of cancer including 
proliferation, survival, invasiveness, metastatic spread and tumour 
angiogenesis (Hanahan & Weinberg, 2000; Herbst, et al., 2008). 
 
1.4.3 EGFR activating mutations  
In 2004, two separate groups of investigators independently identified somatic 
mutations in the EGFR gene in NSCLC adenocarcinomas (Ladanyi & Pao, 
2008). These mutations were found in approximately 10% of tumours from 
patients in the United States and in 30-50% of tumours from patients in Asia 
(Herbst, et al., 2008; Pao, et al., 2011).  
Approximately 90% of lung-cancer-specific EGFR mutations were shown to 
affect a few specific amino acid residues. These gain of function mutations 
comprise either a leucine-to-arginine substitution at codon position 858 
(L858R) in exon 21 or a deletion in exon 19 that affects the conserved 
sequence, leucine-arginine-glutamic acid-alanine motif (LREA), centred 
around codons 746-750 (delE746-A750) (Dacic, Shuai, Yousem, Ohori, & 
Nikiforova, 2010; Pao, et al., 2011; R. Rosell et al., 2009). The in-frame 
deletions in exon 19 make up 45% to 50% of mutations, while the missense 
mutation in exon 21 makes up 35% to 45% (Sequist, Bell, Lynch, & Haber, 
2007).  Both of these mutations are present in the part of the gene that encodes 
the tyrosine kinase (TK) domain of EGFR (Figure 3).  
Significantly, investigators found that regardless of ethnicity these mutations 
are present in NSCLC tumours of never smokers (defined as smoked less than 
100 cigarettes in a patient’s lifetime), female sex, and with adenocarcinoma 
histology (Pao, et al., 2011). Furthermore, the frequency of EGFR mutations is 
inversely associated with cumulative smoking exposure suggesting a strong 
correlation EGFR mutations and the development of lung cancer in non-
smokers (Yano, et al., 2011). Several other mutations in the TK domain of 
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EGFR have been reported (Appendix I), yet the clinical significance of these 
rare mutations has yet to be determined (Pao & Girard, 2010).  
 
Figure 3 EGFR tyrosine kinase domain (Exons 18 – Exon 24) showing LREA deletion in Exon 19 
and missense mutation L858R in Exon 21. Adapted from Yano et al. (2011) 
 
1.4.4 Role of EGFR activating mutations in NSCLC 
EGFR mutations in the tyrosine kinase (TK) domain of the receptor are 
considered gain of function, or activating mutations, as the protein produced 
from a mutated EGFR gene has a constituently active TK activity (Kosaka, et 
al., 2004). It has been shown that these mutations disrupt the auto-inhibitory 
interactions within the TK domain and consequently cause the induction of 
higher phosphorylation of EGFR compared with the wild-type protein (Yatabe 
& Mitsudomi, 2007).  
Whilst under physiological conditions ligand binding is required for the 
activation of EGFR, these mutations enable independent receptor activation 
(Sharma, et al., 2007). This ligand-independent activation EGFR results in 
constitutive signal transduction and an increase in downstream signalling. 
Indeed, crystal structure analyses of wild-type and L858R EGFR have shown 
that the substitution of lysine with arginine results in a much larger side chain, 
which locks the protein in a constitutively active state (Pao, et al., 2011). 
Whereas the LREA deletion results in an altered amino-acid sequence adjacent 
to the ATP binding cleft of EGFR mutant, conferring not only ligand-
dependant activation, but also increasing the duration and activation of receptor 
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signalling after ligand binding compared with wild-type receptor (Rafael 
Rosell et al., 2010). 
As such, through the activation of increased EGFR signalling, these mutations 
confer a selective advantage for these cells, to which the malignant cells 
become dependent. Indeed, the tumour cells require the increased EGFR-
mediated anti-apoptotic signalling merely to sustain survival and are highly 
sensitive to any interruption of these pathways. As a consequence, in 
developing their malignancy, these cells become more dependent on the 
oncogenic activation of EGFR and thus provide an ideal target for anti-cancer 
therapy (discussed further in sections 1.7.1 and 1.8.2) (Yoshida, Zhang, & 
Haura, 2010).  
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1.5 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
The KRAS gene encodes a small quinine nucleotide transferase molecule that links 
cell surface receptors, including EGFR, to their associated intracellular pathways 
(Franklin, et al., 2010). KRAS is a member of the Ras superfamily which are 
characterised by the presence of a catalytic G domain and play a crucial role in the 
transduction extra- and intra-cellular signalling (Jančík, Drábek, Radzioch, & 
Hajdúch, 2010). 
The product of the KRAS gene is a 21.6kDa protein composed of 188 amino acid 
residues. The KRAS protein plays a key role in the kinase cascades such as 
RAS/MAPK/ERK, PI3K/AKT/STAT3 and STAT5 signalling pathways involved 
in a number of cellular processes including proliferation, differentiation and 
apoptosis (O’Hagan & Heyer, 2011).  
 
1.5.1 KRAS role in EGFR cellular pathway 
KRAS is a key member of the EGFR pathway, and can be thought of as a 
signal switch molecule that couples the EGFR receptor activation to 
downstream effector pathways (Schubbert, et al., 2007). Indeed, KRAS cycles 
between active guanosine triphosphate (GTP)-bound and inactive guanosine 
diphosphate (GDP)-bound forms whereby the active form of the protein binds 
to more than 20 effector proteins and stimulates downstream signalling 
cascades (Suda, Tomizawa, & Mitsudomi, 2010).  
Additionally, the KRAS protein has intrinsic GTPase activity, which plays an 
important role in signal transduction through multiple downstream transducers, 
or GTPase-activating proteins (GAPs), which amplify the GTPase activity of 
the KRAS protein 100,000-fold (Jančík, et al., 2010). Accordingly, as seen in 
Figure 2, KRAS is an important early downstream mediator of EGFR-induced 
cell signalling (Rafael Rosell, et al., 2010).    
 
1.5.2 KRAS activating mutations 
KRAS was first identified as an oncogene in 1982 and is now recognised as one 
of the most frequently mutated oncogenes in human cancer (Pritchard, Akagi, 
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Reddy, Joseph, & Tait, 2010).  Accordingly, activating KRAS mutations are 
commonly present in epithelial malignancies, accounting for about 30% of all 
human cancers (O’Hagan & Heyer, 2011). Significantly, KRAS mutations are 
prevalent in pancreatic, colorectal, endometrial, biliary tact, cervical and lung 
cancers (Schubbert, et al., 2007). 
Indeed, tumours harbouring KRAS mutations are often characterised as highly 
aggressive cancers, and consequently the presence of these mutations 
correlated with a poor prognosis in NSCLC (Bunn, et al., 2000; Pritchard, et 
al., 2010; Schubbert, et al., 2007). More than 95% of lung-cancer-specific 
KRAS mutations affect two specific amino acids in codon 12 or 13 in exon 2 of 
the gene (Table 1). These gain of function mutations comprise single-point 
substitutions that change the glycine encoded at both these codons (Pritchard, 
et al., 2010).  
These oncogenic point mutations impair the intrinsic GTPase activity of the 
KRAS protein and confer resistance to GAPs thereby causing the protein to 
accumulate in its active GTP-bound state (Franklin, et al., 2010). As such, 
KRAS proteins encoded by a mutated KRAS gene have lost the intrinsic 
negative-feedback control of their activity, leaving the mutated protein 
constitutively activated, resulting in the dysregulation of the associated key 
cellular pathways (Jančík, et al., 2010). 
 
 
Table 1 Activating missense KRAS mutations in NSCLC. Adapted from Kristensen et al. (2010) 
Exon Codon Nucleotide change Amino acid change 
2 12 (GGT) c.35G>C p.Gly12Ala 
  c.35G>A p.Gly12Asp 
  c.34G>C p.Gly12Arg 
  c.34G>T p.Gly12Cys 
  c.34G>A p.Gly12Ser 
  c.35G>T p.Gly12Val 
 13 (GGC) c.38G>A p.Gly13Asp 
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1.5.3 Role of KRAS activating mutations in NSCLC 
KRAS oncogenic mutations activate the KRAS protein independently of ligand 
binding to EGFR, and subsequently enable the transmission of the associated 
signalling pathways independently of EGFR (Kristensen et al., 2010). 
Specifically, activating KRAS mutations led to activation of the RAS/MAPK 
pathway, inducing multiple cellular processes including proliferation and 
differentiation leading to tumour growth (Zuo et al., 2009). 
While the reported rate of KRAS mutations in NSCLC patients varies 
significantly with ethnicity, their presence is routinely concomitant with a 
history of tobacco smoking and poor prognosis (Bearz, Berretta, Lleshi, & 
Tirelli, 2011; Provencio, et al., 2009). As such they occur predominately in 
Caucasian patients with an incidence rate of about 33% whereas they are only 
present in 10% of East Asian patients (H. Do, Krypuy, Mitchell, Fox, & 
Dobrovic, 2008; Kristensen, et al., 2010). Further, KRAS mutations are found 
predominately in the adenocarcinoma histological subtype of NSCLC, rarely in 
squamous cell carcinoma and never in SCLC (Borras et al., 2011; Suda, et al., 
2010).  
Genetically engineered animal models have provided invaluable information 
about the role of activating mutations in NSCLC (O’Hagan & Heyer, 2011). 
Indeed, nicotine-derived nitroaminoketone (NNK), a potent tobacco-specific 
carcinogen, has been shown to readily induce KRAS missense mutations in 
rodents especially at codon 12, further highlighting the significant association 
between smoking and KRAS mutations (Borras, et al., 2011; Sun, et al., 2007).  
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1.6 Clinical Significance of EGFR and KRAS mutations in NSCLC 
While NSCLC tumours harbouring EGFR or KRAS mutations look the same 
under a microscope, their underlying genetic and molecular makeup is 
significantly different. Given that both EGFR and KRAS mutations have been 
shown to play an important role in the pathogenesis of NSCLC adenocarcinomas 
and have a strictly mutually exclusive relationship, it has been proposed that they 
have functionally equivalent roles in tumourigenesis (Kosaka, et al., 2004; Pao et 
al., 2005).  
This has led to the hypothesis that the mutation status of these two oncogenes 
defines the two clinically relevant molecular subsets of NSCLC, in that EGFR 
mutations are vital to the pathogenesis of non-smoking NSCLC while KRAS 
mutations are limited to driving the smoking-associated NSCLC. The emergence 
of these two genotypically different tumours has contributed to a paradigm shift, 
in that the molecular structure and function of NSCLC tumours is considered to 
be more useful than histological type in predicting the aggressiveness, sensitivity 
to therapy and prognosis (as presented in Table 2) (Works & Gallucci, 1996).  
The emergence of clinical and epidemiological studies focused on the biological 
and genetic difference between smoking- and non-smoking associated NSCLC 
and their associated risk factors, has provided further evidence for the need to 
classify NSCLC tumours on the basis of the mutational status of these two 
oncogenes. Indeed, elucidating these differences has provided researchers with 
promising new anti-cancer therapies which have been developed with the goal of 
longer survival or an amelioration of symptoms (Herbst, et al., 2008; Nose, 
Uramoto, Iwata, Hanagiri, & Yasumoto, 2011). 
 
1.6.1 EGFR and KRAS as oncogenic ‘driver’ mutations 
EGFR and KRAS mutations are considered ‘driver’ mutations in NSCLC as 
their presence is thought to be crucial not only for the establishment, but also 
the viability of the tumour (Pao, et al., 2011). In an experiment which 
compared tumour tissue with matched normal tissue from NSCLC patients, 
KRAS and EGFR where shown to arise somatically during tumour formation, 
providing further evidence for the importance of these mutations as an early 
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oncogenic event in the development of NSCLC (Jimeno & Hidalgo, 2006). 
Indeed, lung cancer can be induced on mice through the generation of KRAS 
exon 12 mutations and the subsequent suppression of this mutated KRAS gene 
in these mice resulted in the reduction and elimination of these tumours 
(Borras, et al., 2011).  
As such, accumulating evidence suggests that these two somatic mutations are 
important oncogenic events in the development and maintenance of the 
malignant phenotype in NSCLC (Yatabe & Mitsudomi, 2007). Consequently, 
EGFR and KRAS mutations are considered to drive carcinogenesis in the two 
disease subtypes, either through the non-smoking EGFR mediated pathway or 
the smoking-associated activated KRAS pathway, respectively.  
 
Table 2 Comparsion of KRAS and EGFR mutations in NSCLC highlighting the key contrasting 
features. Adapted from Kristensen et al. (2010) 
 KRAS EGFR 
Discovery of mutation 1982 2004 
Biochemical function Small GTP-binding protein Receptor tyrosine kinase 
Common mutations Missense mutation at codons 
12 or 13  
Exon 19 LREA deletion, 
missense mutation at codon 
858 (L858R) in Exon 21 
Mutation effect Impaired GTPase-activity 
resulting in constitutive 
activation   
Loss of auto-inhibitory 
feedback in tyrosine kinase 
domain  
Mutation in tumours other 
than NSCLC 
Common – pancreas, colon, 
bile duct etc. 
Rare 
Smoking status Smokers Non-smokers 
Ethnicity Caucasians > East Asians East Asians > Caucasians 
Sex Male > Female Female > Male 
Histology Adenocarcinoma Adenocarcinoma 
Prognostic impact Poorer Better 
Response Rate for EGFR-
TKI therapy 
0% 70-90% 
 
 
17 
 
1.7 Targeted therapies in NSCLC 
Targeted therapies are drugs or other substances that block the growth and spread 
of cancer by interfering with specific molecules involved in tumourigenesis and 
progression (Squassina et al., 2010). Given the high mortality rate associated with 
NSCLC, current treatment paradigms are shifting from cytotoxic chemotherapy to 
molecular targeted therapies in the aim of reducing side-effects and circumventing 
the therapeutic plateau reached by traditional chemotherapy (Pao, et al., 2011).  
Accordingly, by selectively targeting cancer-specific characteristics, targeted 
therapies may be more effective than chemotherapy and less harmful to normal 
cells (Gazdar, 2010). Indeed, targeted therapies have provided some improvement 
in clinical outcomes and as a consequence there has been an explosion in number 
of targeted therapies employed for the therapeutic treatment of many cancers, 
including NSCLC (Hirsch, 2009).  
 
1.7.1 EGFR Tyrosine Kinase Inhibitors 
Given the biological importance of EGFR and its associated molecular 
pathways, several molecules have been developed to inhibit EGFR in attempt 
to block EGFR signalling. As such, EGFR antibodies have been successfully 
introduced for the treatment of colon cancer, while EGFR specific inhibitors 
have been introduced for the treatment of lung cancer (Ansari, et al., 2009; 
Mancl, Kolesar, & Vermeulen, 2009).  
EGFR tyrosine kinase inhibitors (TKIs) specifically inhibit the tyrosine kinase 
(TK) domain of EGFR and have been investigated as first-line or subsequent 
therapeutic options for patients with advanced NSCLC (Gazdar, 2010). These 
EGFR-TKIs are orally active, small molecular weight quinazolinamine 
derivatives (Figure 3) (Jimeno & Hidalgo, 2006; Pao, et al., 2005). They 
selectively inhibit EGFR-mediated cellular signalling by binding to the 
adenosine triphosphate (ATP) binding pocket of the TK domain of EGFR, and 
consequently block downstream signalling (Nomoto et al., 2006).  
As such, EGFR-TKIs cause apoptosis in cancer cells due to the shutdown of 
PI3K-Akt and ERK1/2 signalling pathways following the inhibition of EGFR 
activation (Takeuchi & Ito, 2010). The rationale behind TKIs is that by 
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targeting EGFR, they can selectively target cancer cells with an oncogenically 
transformed EGFR, given that these cells are more dependent on EGFR-
mediated signalling for survival and homeostasis. Indeed, there are only minor 
common side effects of EGFR-TKIs, including the development of a rash and 
acne or diarrhoea, and unlike traditional cytotoxic agents they do not cause 
myelosuppression, neuropathy, alopecia and severe nausea (Mok, 2009).  
 
 
 
 
 
 
 
 
 
 
Figure 4 Chemical structures of EGFR-TKIs gefitinib and erlotinib. These EGFR-TKIs act as 
competitive inhibitors by competing with ATP for the ATP-binding site of the TK domain of the 
EGFR receptor. Adapted from Mok (2009) 
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1.7.2 Gefitinib and Erlotinib 
There are currently two EGFR specific TKIs, gefitinib and erlotinib, employed 
in the treatment of advanced NSCLC (Santarpia et al., 2011). Gefitinib (Iressa) 
was the first to be approved by the US Food and Drug Administration (FDA) in 
2003 (Allison, 2010). Erlotinib (Tarceva) was approved in 2004 by the FDA 
and the European Medicines Agency in 2005 as a second-line therapy for those 
NSCLC patients with advanced or metastatic tumours (Penzel et al., 2011).  
Both these drugs have been shown to reversibly and selectively target EGFR 
and block signal transduction with minimal activity against other tyrosine and 
serine/threonine kinases (Masago, et al., 2008). Current clinical practice in 
most of the world, including NZ, is to use EGFR-TKIs as second- or third-line 
therapy in advanced NSCLC (Sequist & Lynch, 2008). As of early 2011, 
gefitinib is licensed in 66 countries for the treatment of NSCLC (Cataldo, et al., 
2011).  
 
1.8 Patient Response to EGFR-TKIs 
EGFR-TKIs have demonstrated activity in advanced NSCLC in the second- and 
third-line setting in several Phase II and III clinical trials (as summarised in 
Appendix II) (Hann & Brahmer, 2007). However, in contrast to conventional 
chemotherapy, EGFR-TKIs appear to be more effective in specific NSCLC 
populations. Indeed, subset analysis of these several large scale clinical trials has 
shown that never smokers, people of Asian descent, patients with adenocarcinoma 
histology and females are more likely to respond to EGFR-TKIs (Fukui et al., 
2008; Wu et al., 2010; Yatabe & Mitsudomi, 2007).  
Specifically, early Phase II trials demonstrated that EGFR TKI monotherapy has 
modest activity in the general NSCLC population, with response rates of about 
12-26% (Cappuzzo et al., 2005; Hann & Brahmer, 2007). However, subsequent 
Phase III trials reported contrasting results, in that tumours in the vast majority of 
patients failed to respond, while a minority showed dramatic tumour shrinkage 
and symptomatic improvement (T.-Y. Kim, Han, & Bang, 2007). 
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1.8.1 Retrospective analysis of Clinical Trials for EGFR-TKIs in 
NSCLC 
Given the variable response to TKIs in the NSCLC population, retrospective 
analysis of Phase II and III clinical trials were undertaken to explain the 
differential therapeutic response shown by certain subsets of NSCLC patients 
(Yatabe & Mitsudomi, 2007).  Consequently, the differential response shown 
by NSCLC patients was attributed to the genetic makeup of their respective 
tumours (Jimeno & Hidalgo, 2006).  
Indeed, while it had already been established that never smokers, females, 
people of Asian descent, and patients with adenocarcinoma histology showed 
therapeutic benefit to TKIs, this correlation was shown to be the result of these 
patients harbouring EGFR-mutant tumours (Pao, et al., 2011; Sequist & Lynch, 
2008).  
 
1.8.2 EGFR activating mutations and hypersensitivity to EGFR-TKIs 
Since their identification in 2004, EGFR activating mutations have shown a 
strong association with positive clinical outcomes in parameters such as 
response rate, time to progression, and overall survival in those patients treated 
with TKIs (Nomoto, et al., 2006). Given that EGFR-TKIs interact with this 
binding cleft in the EGFR protein, it is thought that these oncogenic mutations 
confer greater sensitivity to TKIs as these drugs to bind more tightly to the 
mutated protein than to the wild-type (Sequist & Lynch, 2008). 
As such, not only do cells with activated EGFR have a better affinity for the 
binding of these competitive inhibitors, but have oncogenic addiction, in that 
they are dependent on EGFR signalling for cellular growth and proliferation 
(C. H. Lin, et al., 2010). As such, it is thought that the mutated EGFR is the 
Achilles heel of these tumours, as the tumour cannot maintain a malignant 
phenotype when EGFR-mediated signalling is interrupted by EGFR-TKIs.  
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1.8.3 EGFR secondary mutations and acquired resistance to TKIs 
Unfortunately, virtually all patients who initially respond to EGFR-TKIs 
eventually develop acquired resistance throughout the course of their treatment 
(Ercan et al., 2010). Studies have shown in approximately 50% of these cases 
that this resistance is due to a secondary mutation, T790M in exon 20 of the 
EGFR gene (Borras, et al., 2011; Provencio, et al., 2009; R. Rosell et al., 
2005).  
The EGFR T790M mutation is oncogenic by itself, but when present in 
conjunction with another EGFR activating mutation, the double mutant leads to 
a substantial increase in EGFR signalling and oncogenic transformation both in 
vivo and in vitro (Ercan, et al., 2010). As such, the T790M mutation is 
associated with a short median progression free survival (PFS) of only 7.7 
months in patients carrying the mutation compared with 16.5 months in those 
without the mutation (Rafael Rosell, et al., 2010). 
 
1.8.3.1 Mechanism of T790M acquired resistance to EGFR-TKIs 
Biochemical studies combined with the molecular analysis of tumour material 
from patients whom have developed resistance have shown that the T790M 
mutation is a common cause of acquired resistance in NSCLC patients. The 
threonine at position 790 is the ‘gatekeeper’ residue as its location at the 
entrance of the hydrophobic pocket of the ATP binding cleft means it has 
important role in determining inhibitor specificity in the receptor (Yun et al., 
2008).   
As such, Yun et al (2008) carried out enzyme kinetic assays using an 
ATP/NADH coupled assay system whereby they could detect the rate of ATP 
hydrolysis in both the wild-type and T790M mutant. The kinetic 
characterisation of the WT and the mutant EGFR kinases revealed a marked 
decrease in the Michealis-Menton constant (Km) for ATP in the drug resistant 
T790M mutant compared with the drug sensitive L858R mutant. Consequently, 
it is now thought that the T790M restores the receptors affinity for ATP, 
enabling ATP to outcompete TKIs for the ATP binding cleft of the tyrosine 
kinase domain, re-establishing signalling from EGFR. 
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1.9 EGFR and KRAS mutations as biomarkers for response to TKIs 
Biomarkers can be used to describe any useful characteristic that can be measured 
and used as an indicator of a normal biological process, a pathological process, a 
pathogenic process or in the case of EGFR and KRAS activating mutations, a 
pharmacologic response to a therapeutic agent, such as EGFR-TKIs (Squassina, et 
al., 2010). The discovery of the association of EGFR and KRAS mutations with 
sensitivity and resistance, respectively, to EGFR-TKIs represents a major 
breakthrough in the application of targeted therapies in NSCLC (van Zandwijk et 
al., 2007).   
Specifically, therapeutic benefit has been seen in approximately 75% of patients 
whose tumours harbour drug-sensitising EGFR mutations, compared with <5% of 
NSCLC patients with wild-type receptor and <1% of patients with KRAS mutant 
tumours (Pao, et al., 2009).  Given this significant association, the detection of 
these predictive biomarkers provides physicians with the opportunity to tailor 
personalised treatment for NSCLC patients. 
 
1.10 Personalised Medicine in NSCLC 
Personalised medicine focuses on the individualised drug treatment of diseases 
according to each patient’s underlying molecular and genetic makeup (Xie & 
Frueh, 2005). Specifically, it refers to the delivery of the right drug to the right 
patient at the right dose. As such, the application of genetic information in order 
to develop targeted strategies is known as pharmacogenomics, whereby those 
individuals likely to respond are identified on the basis of a wide range of data, 
the most important of which are environmental and genetic factors (Squassina, et 
al., 2010).  
Given the significant variability in patient response to EGFR-TKIs, the 
development of treatment decisions based on the expression of genetic biomarkers 
facilitates the translation from research to clinical usefulness, as well as the 
establishment of more effective and cost-saving pathways for patient treatment. 
As such, the goal of personalised medicine is to maximise the likelihood of 
therapeutic benefit and minimise adverse reactions, in attempt to optimise patient 
treatment. This is of particular importance in NSCLC given the modest 
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improvements in quality of life and overall survival with traditional 
chemotherapy, the high mortality and prevalence of the disease, and the burden 
that patient management places on the public health system (Triano, et al., 2010). 
 
1.11 Importance of developing clinically relevant assay to detect EGFR 
and KRAS mutations 
The advent of personalised medicine represents a paradigm shift in the treatment 
of NSCLC, whereby the genetic and molecular characterisation of a patients 
tumour is more important than the histological typing to guide treatment regimens 
and predict patient response (Cho, 2007). As such, gaining knowledge of the 
genetic and molecular characteristics of an individual patient’s tumour has 
become an essential step for treatment decision-making in NSCLC (Luthra & 
Zuo, 2009).  
Indeed, given the growing evidence that the mutation profile of individual 
tumours is highly predictive of patient response to EGFR-TKIs, they must be 
analysed in specific populations (Pierre-Jean & William, 2012). As such, the 
establishment of a clinically relevant assay to detect EGFR and KRAS mutations 
in NSCLC patients is crucial for the translation of genetic information in a clinical 
setting to aid decision making and personalised treatment. Given that clinical 
trials have shown response rates are as low as 12% in unselected patients  
receiving EGFR-TKIs, and one round of treatment with gefitinib costs over 
US$10,000, there is significant economic value in pre-screening patients for these 
predictive biomarkers in NSCLC patients  (Cappuzzo, et al., 2005; Dacic, et al., 
2010).  
Due to the highly predictive nature of EGFR and KRAS mutations for patient 
response, or lack thereof, to EGFR-TKIs, the establishment of an accurate, rapid 
and inexpensive assay to stratify patients on the basis of the mutation status of 
their tumours would enable the selection of optimal therapy and ultimately 
improve patient outcomes.  
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1.11.1 Obstacles in development of clinically relevant assay to detect 
EGFR and KRAS mutations 
The routine molecular classification of NSCLC tumours in clinical practice 
requires a diagnostic assay which is accurate, rapid, cost effective,  and 
requires little effort to optimise, perform and analyse (Milbury, Li, & 
Makrigiorgos, 2009). As such, there is a significant need to establish of a rapid 
and robust assay for the detection of EGFR and KRAS mutations in NSCLC 
patient tumours (Krypuy, Newnham, Thomas, Conron, & Dobrovic, 2006).  
However, there are many obstacles that limit the sensitivity and selectivity of 
current diagnostic techniques, which has contributed to the lack of guidelines 
for mutation testing and other DNA analysis in clinical practice (Squassina, et 
al., 2010). Indeed, there are several constraints placed on the establishment of a 
clinically relevant assay to detect EGFR and KRAS mutations in NSCLC 
patients, the most important of which will be discussed in the following 
sections. 
 
1.11.1.1 Biopsy Specimens 
As surgical resection is not a viable for most NSCLC patients, biopsy 
specimens of patient tumours are taken via fine-needle aspiration. Fine needle 
aspiration biopsy, while reducing the discomfort for the patient, creates 
potential problems for genetic testing of specimens. Indeed, while these fine-
needle aspirates provide sufficient tumour tissue for histological classification 
by a pathologist, the limited tissue can result in a number of false negatives in 
genetic testing, whereby the presence of a mutation can go undetected (Sequist, 
et al., 2007). 
As such, these tumour specimens tend to vary in size, not only in the overall 
specimen size, but also in the ratio of tumour to normal tissue, which further 
limits the sensitivity of screening procedures due to the lack of mutated alleles 
and/or the background of wild-type alleles (da Cunha Santos, Saieg, Geddie, & 
Leighl, 2011). Consequently, some researchers have suggested that the small 
number of EGFR mutation positive results seen in NSCLC patients has limited 
the statistical significance of the association of these mutations with drug 
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response, hindering the application of genetic information in order to stratify 
patients and develop targeted therapies (Squassina, et al., 2010).  
 
1.11.1.2 FFPE Specimens 
Biological specimens, including those taken from NSCLC patients, are fixed 
using formalin and embedded in paraffin wax for the use in clinical pathology 
and long-term storage. Indeed, formalin-fixed, paraffin embedded (FFPE) 
specimens are an invaluable source of genomic DNA and have been 
extensively utilised in genetic studies and retrospective analysis of diseases 
(Furuta et al., 2006). However, the chemical processes involved in the fixation 
of biological specimens hinder the diagnostic techniques involved in the 
development of our understanding at the molecular level.  
Specifically, chemical reactions occur between formaldehyde, the active 
component of formalin, and the genomic DNA within the specimen. Such 
reactions include methylol formation, methylene bridge formation, apurinic 
and apyrmidinic site formation and hydrolysis of phosphodiester bonds 
(Hongdo Do & Dobrovic, 2009). These reactions cause the DNA and other 
nucleic acids to become degraded and fragmented which is problematic during 
PCR thermocycling as it creates “blocks” for the DNA polymerase (Farrugia, 
Keyser, & Ludes, 2010). 
Indeed, as PCR is a universal first step utilised by most molecular diagnostic 
techniques, this limits the sensitivity of almost all established procedures. 
Accordingly, the failure of PCR using FFPE specimens due to the generation 
of DNA-protein cross-linkages and nucleic acid fragmentation is a 
considerable obstacle it the establishment of a clinically relevant assay. Steps 
have been made to combat this, which include the design of primer sets that 
give PCR products less than 300base pairs (bp), the use of high-fidelity DNA 
Taq polymerase with proofreading and exonuclease activity and the extensive 
optimisation PCR conditions for amplification.  
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1.11.1.3 DNA extraction from FFPE specimens 
The DNA-protein cross-linkages and nucleic acid fragmentation as are result of 
FFPE also complicates the isolation of quality genomic DNA from these 
specimens (Farrugia, et al., 2010). In attempt to combat this, a number of 
different protocols have been developed for the extraction of DNA from FFPE 
specimens, which vary in terms of their complication, turnaround time and 
reported degrees of success (Siwoski et al., 2002). Several studies have been 
conducted to compare the efficacy and suitability of these for clinical assays, 
yet given the complicated and expensive reagents used in the majority of these 
methods, none have been established for the routine use on a large scale 
clinical setting.  
Such methods include the phenol-chloroform method, xylene/ethanol method, 
ammonium acetate precipitation, mineral oil, antigen retrieval principle 
(heating under influence of pH), and commercially available kits based on 
silica binding principle and other methods are becoming readily available 
(Farrugia et al 2010). 
 
1.11.1.4 Direct Sequencing  
Direct sequencing is considered the ‘gold standard’ for mutations screening 
and is commonly employed for genotyping biological specimens. However, 
direct sequencing has a sensitivity limit of 20%, whereby it is unable to detect 
mutations present in a specimen below this frequency (Morlan, Baker, & 
Sinicropi, 2009; Uhara et al., 2009). As such, recent studies have shown that 
the use of direct sequencing for EGFR and KRAS mutation detection in FFPE 
NSCLC specimens results in a number of false-negatives, whereby the 
presence of these oncogenic mutations will go undetected. 
Indeed, due to the highly heterogeneous nature of NSCLC tumour specimens, 
and biopsy specimens being contaminated with normal cells, these clinical 
relevant mutations are extensively diluted in wild-type alleles below the 
detection limit of conventional PCR-direct sequencing based assays, requiring 
the need for other DNA screening and diagnostic techniques (Kristensen, et al., 
2010). 
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1.12 Purpose and Scope of Investigation 
The mutation status of the two oncogenes, EGFR and KRAS, has shown 
noticeable variation in the NSCLC disease phenotypes present in either non-
smokers or current and former smokers. Given the clinical significance of these 
mutations, the development and optimisation of PCR-based methods for their 
detection is crucial for the establishment of personalised patient management.   
The primary focus of this investigation is the detection of EGFR and KRAS 
mutations in FFPE specimens. As such, this investigation will attempt to address 
the obstacles outlined above by investigating the use of a variety of genotyping 
and mutation detection protocols, in attempt to establish a clinically relevant 
EGFR and KRAS mutation detection assay for the use on FFPE NSCLC 
specimens. 
As such, clinically relevant diagnostic assays must address the sensitivity limit of 
standard PCR and direct sequencing. In attempt to do so, several other methods 
have established for DNA diagnostics, with greater sensitivity and selectivity for 
mutation detection. However, these methods are limited, due to the requirement of 
increased post-PCR manipulation, cost of reagents and equipment and timely 
nature of these procedures, which is problematic for the clinical application of 
these assays. 
 
1.13 Experimental methods and assay design 
Given that PCR may fail to detect mutations when there is a high ‘background’ of 
wild-type DNA in a specimen, the optimisation of PCR conditions for the 
amplification of genomic DNA from biological specimens is crucial to increase 
the sensitivity of any downstream analysis. As such, several protocols will be 
employed to address the sensitivity limit of standard PCR and direct sequencing. 
These protocols will briefly be introduced in the subsequent paragraphs and 
summarised in Figure 5.  
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1.13.1 COLD-PCR 
Co-amplification at Lower Denaturation temperature (COLD-PCR) is a 
modification of conventional PCR to selectively amplify mutant alleles in a 
wild type background (Zuo, et al., 2009). This method is based on the 
observation that a given DNA sequence has a critical denaturation temperature 
(Tc), which is lower than its melting temperature (Tm). This Tc is defined as the 
temperature below which PCR amplification efficiency for that sequence drops 
significantly (Li et al., 2008).  
The principle behind COLD-PCR is that a single nucleotide mismatch 
anywhere along a double-stranded DNA sequence will generate a small but 
predictable change in the melting temperature (Tm) for that given sequence (Li 
& Makrigiorgos, 2009). Specifically, depending on the context and position of 
the mismatch, a mutation can change the Tm of a sequence by 0.2-1.5
o
C in 
sequences up to 200bp long.  
Indeed, PCR with the denaturation temperature, set to  Tc during thermocycling 
contributes to the selective amplification of minority (mutated) alleles, as it 
results in mainly heteroduplexes (formed by the hybridisation of mutant and 
wild-type sequences) to be denatured and amplified, and leaves the wild-type 
homoduplexes double-stranded and not amplified efficiently (Milbury, et al., 
2009; Zuo, et al., 2009).  As such, COLD-PCR is of particular value, as 
changing a single parameter of thermocycling during PCR is a cost-effective 
way to increase the sensitivity of PCR-based methods for mutation detection.  
 
1.13.2 Restriction Enzyme Digestion mediated mutant enrichment PCR 
Restriction Enzyme digest-mediated mutant enrichment PCR is a two-step 
PCR method with intermittent restrictive digestion. The restrictive digestion 
selectively eliminates the wild-type genes, resulting in the enrichment of 
mutant alleles for the second round of amplification (He et al., 2009). As such, 
the mutant-enriched PCR is an assay with a high specificity and sensitivity that 
can detect one mutant gene among as many as 10
3
 to 10
4
 copies of the wild-
type gene (Asano et al., 2006). 
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Simply, a first round of PCR is carried out on the genomic DNA isolated from 
the specimen and this product is then incubated with the restriction enzyme 
which will cut the DNA at its corresponding recognition site. An aliquot of this 
digestion product is then used as the template for a second round of PCR. 
During PCR of the digestion product, the mutant sequences will be selectively 
amplified, as the digested wild-type sequences will not be amplified with the 
same efficiency (Hlinkova, Babal, Berzinec, Majer, & Ilencikova, 2011a). 
The amplification products from the second round of PCR are subjected to 
analysis via electrophoresis on a polyacrylamide gel. As such, mutation 
containing specimens will show a different banding pattern when compared to 
the control. Indeed, this method requires a fair amount of post-PCR processing 
which results in a time-consuming and labour intensive protocol. Further, 
genotyping via restriction digestion and PAGE gels can be confounded by a 
number of complicating factors including variation in DNA quantity and 
variability of silver staining.  
 
1.13.3 Single-stranded Conformation Polymorphism  
Single-stranded Conformation Polymorphism (SSCP) is a well-established 
method of detecting low level mutations in a background of wild-type alleles. 
Mutation detection by SSCP relies on the fact that when PCR product is 
denatured, the resultant single-stranded DNA, when cooled rapidly, adopts 
secondary conformations according to sequence (Jacobson, 1998). When a 
sample containing a mutated single stranded PCR product is electrophoresed 
on an acrylamide gel, the mutant DNA, because it has a different sequence, and 
hence conformation, compared to normal controls, will display altered 
migration. 
As such, SSCP is of particular value because it can detect the presence of 
genetic aberrations which may not be detected by direct sequencing because of 
sequence masking by background normal sequences (Hu et al., 2007). Hence, 
SSCP is a simple, although only moderately sensitive, technique for screening 
PCR products for the presence of mutant sequences. However, due to the need 
for gel conformation SSCP requires a lot of post-PCR processing and handling, 
30 
 
this increases the turnaround time and the chance of contamination. Indeed, 
complications including inconsistent and time consuming silver staining of 
SSCP gels confound the interpretation of SSCP evidence. 
 
1.13.4 DNA melt curves analysis 
DNA melt curve analysis, in particular high resolution DNA melting (HRM) 
analysis, is a relatively new method for detecting mutations that are present in 
specimens with increased specificity and sensitivity compared with previously 
mentioned protocols. Indeed, it is reported that conventional PCR followed by 
HRM has a mutant detection limit of 2% (Fassina et al., 2009; Penzel, et al., 
2011).  
Mutation detection by DNA melt curve analysis relies on the fact that when a 
PCR product is heated in the presence of an intercalating dye, the melting 
profile of the sequence can be monitored. Indeed, the melting profile is 
dependent on the DNA sequence, and any mutations will result in the 
formation of heteroduplexes which have a different melt profile (Reed, Kent, & 
Wittwer, 2007).  
As such, DNA melt curve analysis is simpler and more cost effective way to 
genotype specimens as it does not require post-PCR processing as analysis can 
be performed on the same instrument. This is highly crucial in clinical practice, 
not only is there reduced chance of contamination, but this will enable timely 
genetic information to aid decision making.  
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Figure 5 Summary of protocols employed in the detection of EGFR exon 19 and exon 21 and KRAS exon 2 mutations in NSCLC FFPE specimens 
DNA melt curve analysis 
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2 Chapter 2                  Materials and 
Methods 
 
2.1 Sample Collection and Identification 
FFPE NSCLC biopsy specimens were selected from the database of archived 
outpatient specimens at the Waikato Hospital (Hamilton, NZ). The sex, histology 
and smoking history of these patients was included alongside the specimen 
reference number. This information was used to select specimens to enrich 
possibility of specimens containing EGFR mutations. Table 2 shows the sex, 
smoking status of the patient, as well as the histological subtype of the six 
specimens that were selected for mutation analysis. 
Once selected, the seven specimens were analysed by an experienced pathologist, 
who identified and marked the areas containing tumour and normal tissue within 
these biopsy specimens. This was done to maximise the collection of tumour 
DNA over normal tissue to reduce the wild-type DNA background. 
Following collection from Waikato hospital, each specimen was kept in a separate 
labelled petri dish to prevent any cross-contamination of or between specimens.  
 
Table 3 FFPE NSCLC specimens selected from Waikato Hospital Outpatient Database. Patient 
reference number, sex, smoking status and the histological subtype of their tumours were the only 
information made available to researchers.  
Specimen Sex Histology Smoking Status 
AUN6654 Female Adenocarcinoma Non-smoker 
PSA1523 Female Adenocarcinoma Non-smoker 
PRF3901  Female NSCLC ?* 
EBT5130 Female ?* Non-smoker 
AWV7836 Female Adenocarcinoma Non-smoker 
EMV8895 Female Adenocarcinoma Non-smoker 
DGZ6804
 Female Adenocarcinoma Non-smoker 
*Information was not available.  
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2.2 DNA extraction/isolation from FFPE Specimens 
A #10 sterile scalpel blade (Swann Morton Ltd) was used to cut 4-6 thin slices 
from the FFPE specimens. These slices were placed in a labelled 1.7mL 
microcentrifuge tube (Axygen) containing 300mL mineral oil and 600mL pH 9 
SDS-lysis solution (1M Tris pH 9, 50mM EDTA, 1% SDS). The tubes were 
mixed in a thermomixer (Eppendorf) at 90
o
C and 900rpm for 20minutes to 
dissolve the paraffin wax. The thermomixer was then cooled to 56
o
C before 
introducing 10µL Proteinase K (0.06g of powder Proteinase K, final conc. 
60µg/µL) to each tube and incubating at this temperate at 600rpm for 4 hours. 
After which, another 10µL Proteinase K was added before incubating at 37
o
C 
(Precision) overnight. 
The following day, the tube was returned to the thermomixer and heated to 56
o
C 
to melt the wax and separate the oil from the specimen, causing the formation of 
separate phases. The bottom phase containing the DNA was removed using a 1mL 
transfer pipette (Raylab) and transferred into a new labelled 1.7mL 
microcentrifuge tube along with an equal volume (approximately 600mL) of 
phenol-chloroform (Sigma). To ensure the phase containing the oil and paraffin 
wax remained in the tube, the pipette tip was placed right to the bottom of the 
tube. The mircocentrifuge tube containing the top oil phase was then discarded. 
The new labelled tube was shaken vigorously by hand to allow the phenol-
chloroform to mix with the specimen, until an emulsion was formed. After which, 
the tube was put on the rotator wheel (Global Science) to continue mixing for 
20minutes. The tube was then centrifuged (5415R Bench Top Centrifuge, 
Eppendorf) at 16.1kRCF for 15minutes. The top phase containing the DNA 
(approximately 400mL) was transferred to new 1.7mL microcentrifuge tube and 
topped up to 600mL with pH 9 SDS-Lysis solution (approximately 100mL). 
100μL 5M NaCl was then added and the specimen was inverted several times to 
mix. Then, 80mL of pre-heated cetrimonium bromide (CTAB) as added before 
incubating the specimen at 65
o
C for 10minutes.  
After which, an equal volume of chloroform (Ajax Finechem Pty Ltd) was added, 
and the tube was placed on the rotator wheel for 20 minutes. Then, the tube was 
centrifuged at 16.1kRCF for 15minutes. The top phase was then removed and 
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transferred to a new labelled 1.7mL mircocentrifuge tube. Following this, an equal 
volume of isopropanol was added and the solution was frozen overnight.  
The following day, the tube was centrifuged at 16.1kRCF for 15minutes. After 
which, the top phase was tipped off and 1mL 70% ethanol was added before 
returning the tube to the centrifuge for 5minutes at 16.1kRCF. Then, the top phase 
was once again tipped off and the tube was centrifuged for 5seconds. Finally, a 
200µL pipette was used to remove the remaining ethanol and the tube was placed 
in the fumehood before resuspending in 50µL TE buffer (10mM Tris, 1mM 
EDTA pH 8).  
 
2.2.1 CTAB Clean up 
Those FFPE specimens which had a poor 260/280 ratio (less than 1.4) were 
subjected to CTAB clean up. Specifically, 470μL TE and 30μL 10% SDS were 
added to the remaining DNA. This was then placed in the thermomixer and 
incubated at 65
o
C and mixed at 900rpm for 10minutes. 
After which, 100μL 5M NaCl was added with 80μL of pre-warmed CTAB and 
further incubated in the thermomixer under the same conditions for 10 minutes. 
Then, an equal volume of chloroform was added, and the tube was placed on 
the rotator wheel for 20 minutes. Then, the tube was centrifuged at 16.1kRCF 
for 15minutes. The top phase was then removed and transferred to a new 
labelled 1.7mL mircocentrifuge tube. Following this, an equal volume of 
isopropanol was added and the solution was frozen overnight.  
The following day, the tube was centrifuged at 16.1kRCF for 15minutes. After 
which, the top phase was tipped off and 1mL 70% ethanol was added before 
returning the tube to the centrifuge for 5minutes at 16.1kRCF. Then, the top 
phase was once again tipped off and the tube was centrifuged for 5seconds. 
Finally, a 200µL pipette was used to remove the remaining ethanol and the 
tube was placed in the fumehood before resuspending in 50µL TE buffer. 
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2.3 A549 NSCLC adenocarcinoma cell line 
The A549 NSCLC adenocarcinoma cell line was developed in 1972 by culturing 
cancerous lung tissue explanted from a 58 year old Caucasian male. Since, 
genotype analysis has shown that the A549 cell line is homozygous for the 
34G>A (G12S) point mutation in KRAS exon 2 (Krypuy, et al., 2006). Indeed, due 
to the strict mutually exclusive relationship KRAS and EGFR mutations, these 
cells are wild-type for activating EGFR exon 19 and exon 21 mutations. 
Therefore, these cells were used as controls throughout the experimental work as 
the mutation status of both KRAS and EGFR genes are known for these cells. 
Consequently, any specimens showing aberrant activity when compared to the 
genomic DNA isolated from these cells was considered indicative of the presence 
of a mutation.  
  
2.4 DNA extraction/isolation from A549 cells 
A549 cell cultures were supplied by Dr Ray Cursons. The cell cultures were 
analysed under the microscope to confirm the presence of A549 cells in the 
medium. After which, the media was tipped off by inverting the flask, and any 
remaining media was removed using a 200µL pipette.  
Then, 1mL of SDS-lysis solution was added to the flask and gently swirled to 
ensure the lysis of the cells adhering to the surface of the flask. Following this, the 
flask was incubated at 37
o
C for 15minutes. After incubation, 500µL of the 
solution was placed in a labelled 1.7mL mircocentrifuge tube containing 1mL 5M 
LiCl (Ajax Finechem Pty Ltd). Then, the tube was mixed until the proteins 
precipitated and the solution turned cloudy. 
Then, approximately 200µL chloroform was added to the mircocentrifuge tube, 
which was vigorously shaken to form an emulsion. After which, the 
mircocentrifuge tube was placed on the rotator wheel for 20minutes. Following 
this, the microcentrifuge tube was transferred to the centrifuge and centrifuged for 
10minutes at 16.1kRCF. 
Then, using a 1mL transfer pipette the aqueous top layer containing the genomic 
DNA was removed and transferred to a new 1.7mL microcentrifuge tube. 
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Following this, 500µL isopropanol was added to the tube and the tube was 
centrifuged for 20minutes at 16.1kRCF. 
Following centrifugation, the supernatant was removed and discarded using a 
1mL transfer pipette, leaving the pellet containing the genomic DNA in the tube. 
Then, the pellet was re-suspended in 1mL 70% ethanol and centrifuged for 
5minutes at 16.1kRCF. After which, the ethanol was tipped off and the tube was 
returned to the centrifuge for 15seconds. Then, using a 200µL pipette the excess 
ethanol was removed before placing the mircocentrifuge tube in the fumehood to 
evaporate the remaining ethanol. Following this, the pellet was re-suspended in 
50µL TE buffer. 
 
2.5 DNA concentration and Purity 
The DNA concentration and purity of each specimen was determined by using 
2µL for analysis using a ND-1000 spectrophotometer (Nanodrop). The 
concentration of nucleic acids was measured by absorbance at 260nm and given in 
ng/µl, while the ratio of 260/280nm indicates the purity of the sample. A ratio of 
1.8-2.0 was ideal, yet is only informative in terms of contamination and does not 
provide information on any DNA degradation that can occur as a result of fixing 
the specimen in formalin.   
The DNA extraction procedure from most specimens was done in duplicate 
(except 19A8 as there was not enough tissue). After the specimens were analysed 
in the Nanodrop, the concentration of genomic DNA was diluted to approximately 
100ng/μL for use in PCR. 
 
2.6 Amplification of EGFR Exon 19 and 21 and KRAS Exon 2 
Based on previous publications (Krypuy, et al., 2006; Nomoto, et al., 2006), 
primers pairs specific for EGFR exon 19 and 21 and KRAS exon 2 were 
synthesised (IDT). 
The primers were supplied at concentrations between 24.0 - 40.5nmol and were 
diluted to 200pmol with TE buffer. For each exon, working primer solutions 
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containing both the forward and reverse primers were made to 20pmol/µL 
concentration. 
 
Table 4 Standard PCR Primers for genotyping using EGFR exon 19 and 21 and KRAS exon 2. The 
base-pair (bp) length of each target region is given. 
Exon Forward (5’ – 3’) Reverse (5’ – 3’) Length 
(bp) 
EGFR 
Exon 19 
AAAATTCCCGTCGCTATC AAGCAGAAACTCACATCG 276 
EGFR 
Exon 21 
AGATCACAGATTTTGGGC ATTCTTTCTCTTCCGCAC 224 
KRAS 
Exon 2 
TCATTATTTTTATTATAAGGCCTGCT
GAA 
CAAAGACTGGTCCTGCACCAGTA 189 
 
A standard PCR protocol was implemented for the amplification of EGFR 
exon 21 and 19 and KRAS exon 2 using the respective set of primers as per 
Table 4. 
 
2.6.1 Optimisation of PCR  
Optimisation of amplification during PCR is important to address the myriad of 
issues when dealing with FFPE specimens, given the quality and quantity of 
the genomic DNA available for these assays is not ideal. Indeed, the 
optimisation of PCR can significantly increase the sensitivity of downstream 
DNA analysis. As such, the conditions for the PCR thermocycling were 
undertaken with different magnesium concentrations as well as with DNA Taq 
polymerase enzymes possessing different fidelities.  
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Table 5 Standard PCR protocol for amplification of EGFR exon 21 and 19 and KRAS exon 2 
Step Temp (
o
C) Time   
1 Initial denaturation and enzyme activation 95 15minutes OR 5 minutes  
2 Denaturation 95 30seconds  
3 Primer annealing 55 30seconds  
4 Extension 72 20seconds  
5 Repeat Steps 2 – 4 for additional 39 cycles    
* Length of activation step different for specific DNA polymerase enzymes. HOTFIRE Taq polymerase required a 
15minute initial activation while FIREPOL Taq polymerase only required a 5minute initial activation. 
 
As such, PCR was performed as per Table 5, with 0.4μM of each primer, 
200μM of each dNTP (A, G, C and T, Solis Biodyne), either 1.5mM or 4.5mM 
MgCl2 and 1.25U/50μL of FIREPOL or HOTFIRE Taq Polymerase enzyme 
(Solis Biodyne) in a final reaction volume of 50μL. The PCR protocol was 
performed on a Thermal cycler (MJ Research). 
 
2.6.2 Agarose Gel Electrophoresis 
The resultant PCR products from Standard PCR were electrophoresed and 
visualised on an Owl gel electrophoresis system to determine amplification of 
the target exons. 
0.66g agarose (SeaKem®) was added to 33mL SB (56g Boric acid, 10g NaOH) 
and heated with intermittent stirring until the agarose had dissolved in the 
solution and no crystals could be seen. After which, the solution was cooled 
under running cold water and 1.25µL ethidium bromide (usb) (3µL/30ml of 
10mg/mL stock solution) was added to the solution and mixed well. Then, the 
solution was poured into a gel castor and two combs were inserted and secured 
in place. The gel was left to set for at least 30minutes.  
10µL of the amplified product from each PCR reaction was mixed with 2µL 
loading dye (0.05% bromophenol blue (Ajax Chemicals), 0.05% Xylene cyanol 
(Sigma), 6% glycerol (Ajax Chemicals)) and loaded into a well of the gel. A 
100bp ladder (Solis BioDyne) was also loaded into one of the wells for 
comparison of PCR product length. The products were then electrophoresed for 
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30mins at 110V and 30mA. Product bands were visualised using a ultra-violet 
light transluminator (TFX-35M, Life technologies), photographed (COHU 
High Performance Camera) and printed. 
 
2.6.3 Purification of PCR products for sequencing  
Following visualisation on the agarose gel, PCR products were purified by 
precipitation with polyethylene glycol (PEG). As such, approximately 40µL of 
the PCR product was transferred to a 1.7mL microcentrifuge tube and an equal 
volume of PEG solution (20% polyethylene glycol 800 in 2.5mM NaCl) was 
added, and the tube was inverted several times to ensure the solution was 
mixed well. Then, the tube was incubated at room temperature for 15minutes.  
After which, the microcentrifuge tube was centrifuged at 16.1kRCF for 
15minutes to cause the DNA to sediment. Then, the supernatant was removed 
leaving the pellet in the tube, and 1mL 100% ethanol was added before 
centrifuging at 16.1kRCF for 5minutes. Following this, the ethanol was 
removed and 1mL 70% ethanol was added before inverting the tube several 
times and centrifuging at 16.1kRCF for another 5minutes. Then, the ethanol 
was tipped off and the tube was centrifuged at 16.1kRCF for 10seconds and the 
remaining ethanol was removed using a 200µL pipette.  
Finally, the pellet was left to dry in the fumehood, before resuspending in 10µL 
Milli-Q H2O (Barnstead). The tube was then vortexed to ensure the 
solubilisation of the DNA and the concentration of DNA was measured using 
the ND-1000 spectrophotometer. The solutions were then sent to the University 
of Waikato Sequencing Facility (Hamilton, NZ), using Applied Biosystems 
3130xl Genetic Analyser and the forward and reverse primers for the 
respective exons.  
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2.7 COLD-PCR 
COLD-PCR takes advantage of the substantial drop in amplification of homo-
duplexes when the denaturation temperature is dropped below the critical 
denaturation temperature (Tc). This enables the selective amplification 
heteroduplexes of mutant and wild-type sequences and enriches the original 
minority mutant sequences (Luthra & Zuo, 2009). This protocol was used in 
attempt to increase the sensitivity of both direct sequencing and high resolution 
melting analysis.  
 
2.7.1 Experimental Determination of Tm and Tc 
To experimentally determine the Tm and Tc of the products produced for 
COLD-PCR using the respective primers for each exon (Table 4), the optimal 
conditions as determined in 2.6.1 were set up, with some modifications for 
Real-time PCR. Accordingly, less primer and Taq DNA polymerase enzyme 
were added and the fluorescent dye, Syto 82 (Invitogen) was introduced.  
As such, Real-time PCR was performed with 0.25μM of each primer, 200μM 
dNTPs, 4.5mM MgCl2 and 0.6U of HOTFIRE Taq Polymerase enzyme and 
0.025mM Syto82 in a final reaction volume of 20μL. The PCR was performed 
on the Real Time Cycler (RotoGene
TM
6000, Corbett Technologies) and melt 
curves where produced using the associated software. These melt curves gave 
both the melting activity and the Tm of the amplicons from which the Tc could 
be determined using the following equation: 
 
                
 
After the Tc of the EGFR exon 21 and 19 and KRAS exon 2 amplicons were 
determined, thermocycling was undertaken with the denaturation temperature 
set to the respective Tc.  
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2.7.2 COLD-PCR amplification of EGFR Exon 19 and 21 and KRAS 
Exon 2 
Reaction conditions for the COLD-PCR amplification of EGFR exon 19 and 
21 and KRAS exon 2 were similar to the conditions outlined in 2.6.1 with slight 
modifications. Specifically, 15 cycles ‘normal cycles’ where carried out before 
dropping the denaturation temperature to Tc for an additional 40 cycles, given 
that beginning with normal cycles is essential to increase the template 
concentration for thermocycling. 
 
Table 6 COLD-PCR Protocol for amplification of EGFR exon 21 and 19 and KRAS exon 2 
Step Temp (
o
C) Time   
1 Initial denaturation and enzyme activation 95 15minutes  
2 Denaturation 95 15seconds  
3 Primer annealing 55 10seconds  
4 Extension 72 15seconds  
5 Repeat Steps 2 – 4 for additional 14 cycles    
6 Denaturation Tc* 15seconds  
7 Primer annealing 55 10seconds  
8 Extension 72 15seconds  
9 Repeat Steps 6 – 8 for 39 more cycles    
 *Tc experimentally determined as per 2.7.1 for each respective exon  
 
As such, PCR was performed on a Thermal Cycler as per Table 6, with 0.4μM 
of each primer, 200μM dNTPs, 4.5mM MgCl2 and 1.25U/50μL of Taq 
Polymerase enzyme in a final reaction volume of 50μL.  
Once the COLD-PCR protocol was carried out, 10µL of each reaction was 
loaded into a 2% (w/v) agarose gel supplemented with ethidum bromide and 
electrophesed as previously described in 2.6.2. Following this, the COLD-PCR 
products were purified and sent to the University of Waikato DNA Sequencing 
Facility, as per 2.6.3. 
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2.8 Restriction Digest-mediated mutant enrichment PCR 
Restriction digest mutant enrichment PCR is a two-step PCR with intermittent 
restriction digestion to eliminate wild-type alleles selectively, thus enriching the 
mutated alleles. Restriction enzymes have recognition sites at which they selective 
cut or ‘digest’ a DNA sequence. As such, restriction enzymes, which have a 
recognition site within the wild-type gene, can be used to selectively digest these 
sequences, increasing the proportion of mutant sequences that can be used for 
templates during amplification in PCR. 
Indeed, restriction enzymes with recognition sites present exclusively in the wild-
type sequences for EGFR exon 19 and 21 were selected (Table 6). The restriction 
enzyme MseI employed for EGFR exon 19 has a recognition site (TTAA). This 
sequence is the first letter of codon 747 (i.e. the first T) to the first letter of codon 
748 (i.e. the last A), which is not present in the LREA deletion mutant. While, 
MscI employed for EGFR exon 21 as it has a recognition site (TGGCCA) 
sequence which is not present in the L858R mutant due to the base substitution of 
T to G at first base of recognition site.  
 
Table 7 Restriction enzymes selected for mutant enrichment PCR of EGFR exon 19 and exon 21. Both 
restriction enzymes have recognition sites that are not present in the mutant.  
Exon  Restriction 
Enzyme 
Recognition 
Site 
Reason why not present in 
mutant sequence 
 
EGFR 
Exon 19 
MseI TTAA First letter of codon 747 to first letter of 
codon 748 – absent in deletion mutant 
 
EGFR 
Exon 21 
MscI TGGCCA GGGCCA in L858R mutant  
 
2.8.1 Restriction digest-mediated mutant enrichment PCR 
amplification of EGFR Exon 19 and 21  
The method employed was a combination of those previously described by 
Asano et al (2006) and Hlinkova et al (2011). Specifically, the first round of 
PCR amplification was done in a 20μL volume with the primers in Table 10. 
Importantly, the second round of PCR was done with a second set of primers 
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inside the first round primers. Reaction conditions for the amplification of 
EGFR exon 19 and 21 were similar to the conditions outlined in 2.6.1 with 
slight alterations.  
 
Table 8 Restriction Digest-mediated mutant enrichmnent PCR protocol for amplification of 
EGFR exon 21 and 19  
Step Temp (
o
C) Time   
1 Initial denaturation and enzyme activation 95 15minutes  
2 Denaturation 95 30seconds  
3 Primer annealing 53 30seconds  
4 Extension 72 20seconds  
5 Repeat Steps 2 – 4 for additional 39 cycles    
6 Final extension 72 10 minutes  
 
 
As such, Restriction digest-mediated mutant enrichment PCR was performed 
on a Thermal Cycler as per Table 8, with 0.4 μM of each primer, 200μM 
dNTPs, 4.5mM MgCl2 and 1U/50μL of HOTFIRE Taq Polymerase enzyme in 
a final reaction volume of 20μL.  
 
2.8.2 Restriction enzyme digestion 
The restriction digest of the first PCR products for EGFR exon 21 was done 
using 2U of MscI (BioLabs). Specifically, a 5µL aliquot of the restriction 
buffer as per Table 9 was added to the 20µL first round PCR reaction. 
The intermittent restriction digest of the first PCR products for EGFR exon 19 
was carried out in a similar way using 2U of Mse1 (BioLabs), 0.25µL BSA and 
only 1.85µL Milli-Q H2O was added to the restriction digest buffer solution as 
per Table 9.  
The tube was incubated at 37
o
C for 4 hours. Then, the restriction enzyme was 
deactivated by increasing the temperature to 65
o
C for 20minutes. 
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Table 9 Restriction digestion incubation conditions for EGFR Exon 21 and Exon 19 
Reagents Volume 
Exon 21                    Exon 19 
10x Buffer 2.5μL 2.5μL 
Milli-Q H2O 2.1μL 1.85μL 
PCR Product 20μL 20μL 
Enzyme* 0.4μL 0.4μL 
BSA - 0.1μL 
*Restriction enzyme was specific to each exon 
 
 
2.8.3 Nested PCR 
Nested PCR achieves greater PCR sensitivity and specificity through the use of 
a second round of PCR. As such, an aliquot of the PCR product is used as the 
template DNA for a second round of PCR with primers designed to amplify a 
smaller DNA region within the primary amplicon i.e. the second primers are 
‘nested’.  
The second round of PCR was performed with 2μL of the digestion product 
from 2.8.2 as the template under the same conditions as the first round of PCR, 
except for two modifications. Specifically, the use of the nested primers (Table 
9) and thermocycling was only carried out for 35 cycles.  The PCR products 
from the second amplification were then analysed on a 13% polyacrylamide 
gel electrophoresis (PAGE) gel with silver staining as described in 2.9.2 and 
2.9.4. 
Specifically, 10µL of the PCR products was mixed with 2µL of loading dye 
and loaded into a well of the gel. A 100bp ladder (BioDyne) was also loaded 
into the gel for restriction fragment length polymorphism analysis. 
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Table 10 Nested Primers for Restriction digest-mediated mutant enrichment PCR 
Exon Forward (5’ – 3’) Reverse (5’ – 3’) 
Round 1   
   Exon 19 GCACCATCTCACAATTGCCAGTTA CCTGAGGTTCAGAGCCATGGA 
   Exon 21 CCATGATGATCTGTCCCTCACA TCCCTGGTGTCAGGAAAATGCT 
Round 2   
   Exon 19 ATCCCAGAAGGTGAGAAAGATAAATTC GAGGTTCAGAGCCATGGACCC 
   Exon 21 CGCAGCATGTCAAGATCACAGAT AGGAAAATGCTGGCTGACCTAAA
G 
Product lengths – exon 19 round 1 = 176bp, exon 19 round 2 = 114bp 
                          – exon 21 round 1 = 194bp, exon 21 round 2 = 122bp 
 
 
2.9 Single-stranded Conformation Polymorphism 
PCR-SSCP is a well-established method used for mutation screening and 
detection in biological specimens, where mutations are often present in at a low 
frequency. This method relies on the fact that a mutation along a sequence will 
result in that sequence adopting a different secondary conformation when heated 
and cooled rapidly.   
 
2.9.1 Production of ssDNA 
PCR products for EGFR exon 19 and 21and KRAS exon 2 were produced as 
per 2.6.1 for the use in SSCP. After amplification, 5µL the PCR products were 
diluted with 15μL of stop buffer (95% formamide 0.05% bromophenol blue, 
0.05% xylene cyanol) and denatured at 95
o
C for 15minutes, and then chilled 
for 10 minutes in a methanol/ice-bath (-20
o
C).  
 
2.9.2 PAGE gels 
Polyacrylamide gels were set up using a Hoefer mighty small SE250/SE260 
gel rig. The glass plates and spacers were cleaned with detergent and tap water, 
wiped dry with paper towels, and then cleaned again with 70% ethanol to 
ensure surfaces were free of any polymerised acrylamide and other debris. 
Prepared plates were then carefully placed in a Hoefer gel caster. Gels were 
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prepared according to the appropriate composition shown in Table 9. 
Ammonium persulfate (APS) and TEMED (N, N,N,N’,N’-tetramethyl-
ethylenediamine) were not added until immediately before casting the gel. The 
gel was prepared in a 50 ml falcon tube (CELLSTAR
®
) then poured 
immediately into the gel caster using a 1mL transfer pipette. When the gel 
caster was full, a 10 tooth comb was put in place. Extra solution was added 
around the comb to ensure the formation of even and deep wells. The gels were 
observed for a few minutes to ensure no leakage. The gel was left to set and if 
was not being used that day were wrapped in gladwrap and stored at 4  C for 
no longer than 1 week. 
 
       Table 11 Composition of 13% PAGE gels 
Reagent Volume 
49:1 Acrylamide:bis (40%) 3mL 
5xTBE 2mL 
50% glycerol 1mL 
H2O 3mL 
TEMED 10µL 
10 % APS (w/v) 100µL 
Sufficient to prepare one 10 x 8 gel.  
 
 
2.9.3 Electrophoresis of ssDNA 
When required, gels were unwrapped and clamped to a Hoefer ‘Mighty Small 
II’ (SE250/SE260) gel electrophoresis unit with a cooling plate. The buffer 
chamber was filled to the appropriate level with 1X TBE (0.45 M Tris,  0.45 M 
Boric Acid, 10mM EDTA) buffer. The comb was removed and wells washed 
to remove any unpolymerised acrylamide from the wells with 1XTBE buffer 
using a 200µL pipette.  
Then, 10μL aliquots of the prepared samples from 2.9.1 were loaded onto the 
polyacrylamide gel with a 10μl pipette. The running conditions were 200 V 
(~30mA) for 3-5 hours at room temperature. 
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2.9.4 Silver Staining of acrylamide gels 
After electrophoresis, the gels were silver stained according to Dr Ray 
Curson’s protocol (2005). Accordingly, the gels were removed from their gel 
plates and washed in fixative solution (10% ethanol 5% acetic acid) for 3 
minutes. Then, the fixative solution was removed using the suction pump 
before soaking the gel in 1% HNO3 for 3 minutes. Once again, the suction 
pump was used to remove the solution and the gel was rinsed in Milli-Q H2O 
for 30 seconds. After the Milli-Q H2O was removed with the suction pump, the 
gel was soaked in 0.1% AgNO3, 150µL HCOOH/100mL for 10 minutes. This 
was removed via the suction pump before rinsing the gel once again in Milli-Q 
H2O for 30 seconds and this was removed. The gels were then allowed to 
develop in the developer solution (3% Na2CO3, 150µL HCOOH, 100µL 10% 
Nathio) until stained bands were visiable. The development was stopped by 
addition of fixative solution (10% acetic acid). The gels were then washed in 
Milli-Q H2O and dried before photographed over a light box and sealed in a 
plastic bag. 
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2.10 DNA melt curve analysis 
DNA melt curve analysis has recently been introduced as a rapid, sensitive an 
inexpensive method for the screening of mutations in a substantial wild-type 
background. As such, it has huge potential for detection of DNA sequence 
changes such as mutations and insertions and deletions (Do et al 2008).  
 
2.10.1 Amplification of EGFR Exon 19 and 21 and KRAS exon 2 with 
Real time PCR 
Real-time PCR for melt curve analysis was performed on the Rotor-Gene 6000 
(Corbett Research) in the presence of the fluorescent DNA intercalating dye, 
Syto 82 (Invitrogen) and primers previously described in Table 4. 
 
 
Table 12 Real-time thermocycling parameters for amplification of EGFR exon 21 and 19 and KRAS 
exon 2 
Step Temp (
o
C) Time   
1 Initial denaturation and enzyme activation 95 15minutes  
2 Denaturation 95 30seconds  
3 Primer annealing 55 30seconds  
4 Extension 72 20seconds  
5 Hold 80 10seconds  
6 Repeat Steps 2 – 5 for additional 39 cycles    
 
 
As such, Real-time PCR was performed as per Table 12, with 0.25μM of each 
primer, 200μM dNTPs, 4.5mM MgCl2 and 0.625U of HOTFIRE Taq 
Polymerase enzyme and 0.025mM Syto82 in a final reaction volume of 20μL. 
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2.10.2 Production of Melt Curves 
Following PCR, products from 2.10.1 were heated from 60°C to 95°C, rising 
by at 0.1-0.2
o
C/sec and the change in fluorescence, as measured by release of 
Syto82, was recorded with the accompanying software. 
 
2.10.3 Melt Curve Analysis 
The melt curves generated from the FFPE specimens in 2.10.3 were compared 
to the melt curves generated using the same protocol for the A549 cell line. 
Samples with a skewed or left-shifted curve from those of control samples are 
judged to have a mutation.  
 
2.11 Analysis of Sequencing Data 
The sequences obtained from the University of Waikato DNA Sequencing facility 
were checked against sequences stored at online database ‘Genebank’ by a 
BLAST analysis. Mutations were identified by comparison between the online 
reference sequences for EGFR (NG_007726.1) and KRAS (NG_007524.1) genes 
on this database and the sequences obtained from the specimens. As such, any 
misalignments were further analysed to elucidate the exact position and 
consequently establish if the mutation was of clinical significance or just an 
experimental artefact. 
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3 Chapter 3      Results 
 
3.1 Isolation of genomic DNA 
Genomic DNA was extracted and isolated from the seven FFPE NSCLC 
specimens using a method adapted from Lin et al (2009). Importantly, our method 
utilised mineral oil and a pH 9 SDS-lysis solution for the efficient removal of 
paraffin wax, contributing to the extraction of a high yield of quality genomic 
DNA from the FFPE specimens.  
 
Table 13 Nanodrop results from DNA extraction and isolation carried out on seven FFPE NSCLC 
specimens and the A549 NSCLC adenocarcinoma cell line. The physical characterisation of the 
specimens was also recorded.  
Specimen  Concentration 
(ng/μL) 
260/280 
Absorbance 
Physical Characterisation of 
FFPE specimen 
24A6 319.7 1.95 Mostly tumour tissue 
54A4 116.7 1.89 Mostly tumour tissue 
98F7 743.4 1.82 All tumour tissue 
77B4 634.7 1.84 Mostly tumour tissue 
34F3 847.9 1.89 Mostly normal tissue 
4674 672.3 1.85 Mostly tumour tissue 
19A8 64.8 1.83 Mostly tumour tissue – very 
small specimen 
A549 cells* 953.9 1.87 N/A 
*A549 NSCLC adenocarcinoma cell line is not a FFPE specimen 
 
 
Table 13 shows the Nanodrop results from one round of DNA extraction (all 
specimens were done in duplicate except 19A8 due to a lack of tissue). The 
concentration of DNA isolated from these specimens was surprisingly high and 
the 260/280 absorbance reading was close to 1.8, indicating a lack of 
contaminants within the DNA sample. However, two specimens, 77B4 and 98F7 
had a low 260/280 reading which indicated the extraction protocol was not able to 
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sufficiently remove other nucleic acids and/or there was some remaining reagents 
left in the DNA pellet. As a consequence, these specimens where subjected CTAB 
clean-up as per 2.3.1 to remove any contamination and the DNA concentration 
and 260/280 absorbance were recalculated (as shown in Table 13). 
Moreover, while most FFPE specimens yielded a significant amount of DNA 
specimen 19A8, which was characterised as having a very small amount of tissue 
(typical of fine needle aspirations from NSCLC patients) yielded significantly less 
genomic DNA. Given that approximately 100ng is required as a DNA template 
for PCR, this low yield of DNA is likely to limit the downstream DNA analysis 
for this specimen.  
 
3.2 Optimisation of Standard PCR  
PCR thermocycling was carried out with differing time periods, temperatures and 
concentrations of reagents to find the optimum conditions to maximise 
amplification in attempt to increase both the sensitivity and robust nature of the 
downstream mutation detection protocols. Specifically, we found that using both a 
PCR buffer with high magnesium concentration and high fidelity Taq DNA 
polymerase enzyme were important to ensure efficient amplification from the 
FFPE specimens. Interestingly, these optimised conditions were not required for 
amplification of DNA isolated from the A549 NSCLC adenocarcinoma cell line, 
further highlighting the importance of optimising PCR conditions when 
amplifying a degraded DNA template. 
 
3.2.1 Magnesium Concentration 
To establish the effect of magnesium concentration on the efficiency of PCR 
amplification from FFPE specimens, the standard PCR protocol as described in 
2.6.1 was carried out with a PCR buffer containing a standard MgCl2 
concentration of 1.5mM and with a PCR buffer with a higher concentration of 
4.5mM MgCl2. Figure 6 and Figure 7 show the results from agarose gel 
electrophoresis conformation of these PCR conditions.  
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Figure 6 Standard PCR amplification of DNA isolated from A549 NSCLC adenocarcinoma cell line 
(Lanes 2-6) and FFPE specimen (Lanes 7-11) using a PCR buffer with a 1.5mM magnesium 
concentration. KRAS exon 2, Ex21 = EGFR exon 21, Ex19 = EGFR exon 19, ß-act = ß-actin 
(housekeeping gene). Lane 1 = 100bp ladder. 
 
 
 
 
Figure 7 Standard PCR amplification of DNA isolated from FFPE specimens (Lanes 2-6) and A549 cell 
line (Lanes 7-11) using a PCR buffer with a 4.5mM magnesium concentration. KRAS = KRAS exon 2, 
Ex21 = EGFR exon 21, Ex19 = EGFR exon 19, ß-act = ß-actin (housekeeping gene) and N = negative 
control. Lane 1 = 100bp ladder. 
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3.2.1.1 Conclusions 
As shown in Figure 6, the PCR buffer possessing a 1.5mM MgCl2
 
concentration was unable to produce amplification products for EGFR exon 21 
and 19, KRAS exon 2 and ß-actin (housekeeping gene) from the FFPE 
specimens, yet was able to amplify the genomic DNA isolated from the A549 
NSCLC adenocarcinoma cell line. In contrast, the PCR buffer possessing a 
4.5mM MgCl2 concentration was able to amplify products from the genomic 
DNA isolated from both the A549 cells and the FFPE specimens (Figure 7). 
Consequently, all subsequent experiments were carried out with a PCR buffer 
with a 4.5mM MgCl2 concentration. 
 
3.2.2 High fidelity Taq DNA polymerase enzyme 
The requirement of a high fidelity Taq DNA polymerase enzyme was determined 
by carrying out the standard PCR protocol as described in 2.6.1 using FIREPOL 
Taq DNA polymerase and HOTFIRE Taq DNA polymerase. HOTFIRE Taq
 
DNA 
Polymerase is a chemically modified FIREPOL DNA polymerase. At ambient 
temperatures it is inactive, having no polymerisation activity as the HOT FIREPol
 
DNA polymerase is activated by a 15 min incubation step at 95°C. This prevents 
extension of non-specifically annealed primers and primer-dimers formed at low 
temperatures during PCR. The enzyme has 5’→3’ polymerization-dependent 
exonuclease replacement activity but lacks 3’→ 5’ exonuclease activity (Solis 
Biodyne Datasheet). 
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Figure 8 Standard PCR amplification of KRAS exon 2 from genomic DNA isolated from FFPE 
specimens (Lanes 3 and 4) and the A549 NSCLC adenocarcinoma cell line (Lane 5) using FIREPOL 
Taq DNA polymerase enzyme. N = negative control, no DNA. Lane 1 = 100bp ladder. 
 
 
 
Figure 9 Standard PCR amplification of KRAS exon 2 from FFPE specimens (Lanes 2 -4 and 6-7) and 
A549 adenocarcinoma cell line (Lane 5) using HOTFIRE Taq DNA polymerase enzyme. Lane 1 = 
100bp ladder.  
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3.2.2.1 Conclusions 
Figures 8 and 9 depict the agarose gel electrophoresis conformation from the 
standard PCR amplification of KRAS exon 2 from the FFPE specimens and A549 
cell line, using these two Taq DNA polymerases. As seen in Figure 8, FIREPOL 
Taq polymerase was only able to produce amplification products from the 
genomic DNA isolated A549 cells, while HOTFIRE Taq polymerase was able to 
produce amplification products from the DNA isolated from both the A549 cells 
and the FFPE specimens (Figure 9). Consequently, all the subsequent experiments 
were carried out using HOTFIRE Taq DNA polymerase. 
 
3.2.3 Confirmation by DNA Sequencing 
Following the elucidation of the optimum thermocycling conditions, the PCR 
products for EGFR exon 21 and 19 and KRAS exon 2 from each of the six 
NSCLC FFPE specimens were purified and sent to the Waikato DNA 
Sequencing facility for direct sequencing to determine if standard PCR 
followed by direct sequencing could detect EGFR and KRAS mutations in the 
NSCLC FFPE specimens. Examples of the electropherograms received for 
each exon are presented in Figures 10-12. 
Both forward and reverse DNA sequences were obtained and checked against 
references stored at online database ‘Genebank’ by a BLAST analysis. 
Mutations were identified by comparison between the online reference 
sequences for EGFR and KRAS genes on this database and the sequences 
obtained from each FFPE specimen. As such, any misalignments were further 
analysed to elucidate the exact position and consequently establish if the 
mutation was clinically significant (present in the ‘mutation hotspots’ of each 
gene) or an experimental artefact.  
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Figure 10 Electropherogram produced from 34F3 NSCLC FFPE specimen for EGFR exon 21. The 
black arrow indicates where the L858R mutation would be present in the exon. In the wild-type 
sequence (as seen here) a lysine (CTG) is encoded by codon 858 however in the mutated sequence 
this changes to an arginine (CCG) at this position. This electropherogram is representative of those 
received for EGFR exon 21 as all specimens except 19A8 (no sequence data for standard PCR 
protocol) showed wild-type sequences in the sequencing data produced from both standard PCR 
and COLD-PCR. 
 
 
 
Figure 11 Electropherogram produced from 54A4 NSCLC FFPE specimen for EGFR exon 19. The 
black arrow indicates were the LREA deletion would be present in the exon. In the wild-type 
sequence this conserved region is present (as shown here), however in the mutated sequence there is 
12-`15bp deletion. This electropherogram is representative of those received for EGFR exon 19 as 
most of the NSCLC FFPE specimens showed a wild-type sequence.  
 
 
 
Figure 12 Electropherogram produced from 98F7 NSCLC FFPE specimen for KRAS exon 2. The 
black arrow indicates were the single point mutation would be present in the exon. In the wild-type 
sequence a glycine (GGT – ACC as reverse sequence shown here) is encoded at codon 12, however 
in the mutated sequence this changes to a different amino acid (outlined in Table 1). This 
electropherogram is representative of those received for KRAS exon 2 as all specimens showed wild-
type sequences in the sequencing data produced from both standard PCR and COLD-PCR.  
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Indeed, of the sequences obtained from the Waikato Sequencing Facility, none 
showed any misalignment indicative of the LREA deletion (EGFR exon 19), 
L858R (EGFR exon 21) or a codon 12 or 13 single point mutation (KRAS exon 
2). Examples of the BLAST alignments along with the sequence data (Table 
23) for the FFPE specimens are in Appendix III. From this data, the genotypes 
for the FFPE specimens, as according to standard PCR and direct sequencing 
were established and presented in Table 14.  
 
Table 14 Genotypes for the six NSCLC FFPE specimens as determined by standard PCR and 
direct sequencing 
Specimen  EGFR Exon 21 EGFR Exon 19 KRAS Exon 2 
24A6 WT WT WT 
54A4 WT WT WT 
98F7 WT WT WT 
77B4 WT ? WT 
34F3 WT WT WT 
19A8 ? ? WT 
WT = wild-type     ? = unable to genotype 
 
Interestingly, the electropherograms received for the forward and reverse 
sequencing reactions from 77B4 specimen (that we were unable to obtain a 
‘clean’ sequencing result for EGFR exon 19), both stopped at the codons that 
directly correspond to the mutation hotspot in EGFR exon 19 were there the 
LREA deletion is present. Specifically, the forward sequencing data stopped at 
codon 746 and the reverse sequencing data stopped at codon 751. This is 
suggestive of the presence of mutation in this specimen, yet due to the 
sensitivity limit of direct sequencing, this protocol was unable to detect this 
deletion in the significant wild-type background. 
Further, in attempt to obtain ‘clean’ electropherogram data and establish a 
genotype for 77B4 EGFR exon 19 and 19A8 EGFR exon 21 and exon 19, the 
PCR products for these specimens were inserted into a plasmid and cloned in 
DH5α E. coli cells (method not shown). However, the sequencing data 
received from the PCR products of the cloned plasmids was also poor in that 
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there was a substantial background in the electropherogram, from which a 
‘clean’ sequence could not be obtained and consequently, the genotypes could 
not be established. 
 
3.2.4 Conclusions 
While this protocol is considered the ‘gold standard’ mutation detection 
technique and is relatively straightforward and a simple to implement, the 
standard PCR and direct sequencing protocol was unable to detect any 
mutations in EGFR and KRAS genes in the genomic DNA isolated from the 
FFPE NSCLC specimens. Given that the PCR conditions, while optimised, did 
not address the sensitivity limit of direct sequencing, further PCR-based 
protocols must be established to enrich for mutations and/or have greater 
sensitivity than the reported 20% of direct sequencing.  
Indeed, these results are consistent with previous reports (Hlinkova, Babal, 
Berzinec, Majer, & Ilencikova, 2011b; Krypuy, et al., 2006; Milbury, et al., 
2009; Miyamae et al., 2010), in that standard PCR followed by direct 
sequencing is unable to detect low level mutations in FFPE specimens, due to 
the poor sensitivity limit of direct sequencing and the inability of PCR to 
differentially amplify mutant sequences. Importantly, while my results report 
that all the NSCLC FFPE specimens for which genotype data could be 
obtained, were wild-type for both EGFR and KRAS, it is also well established 
that the use of this protocol does result in a number of false negatives (Takano 
et al., 2007).  
 
3.3 COLD-PCR 
It has been reported that COLD-PCR can increase the sensitivity of PCR-based 
mutation detection assays by up to 100-fold. Indeed, by changing a single 
parameter of PCR (the denaturation temperature), this method is relatively easy to 
implement and is cost-effective in terms of reagents and equipment required.  
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3.3.1 Experimentally derived Tc 
The crucial step in this protocol is the establishment of the Tc for each of the 
amplicons, which is used as the lower denaturation temperature during 
thermocycling. As such, the NSCLC adenocarcinoma A549 cell line was used 
to experimentally determine the critical denaturation temperature (Tc) of the 
amplicons produced for EGFR exons 19 and exon 21 and KRAS exon 2. 
Importantly, A549 cells are wild-type for EGFR activating mutations and 
homozygous for KRAS codon 12 mutations. As such, these cells provided an 
ideal way to experimentally determine the lowest denaturation temperature at 
which the homoduplexes would separate.  
The results of the experimental determination of Tc from 2.7.1 are presented in 
Table 15. The Tm was established as the melting temperature of the 
homoduplexes for each of the three exons and the Tc was calculated from this 
using the previously described calculation in 2.7.1.   
Additionally, while our experimentally determined Tc for the KRAS amplicon 
was found to be 81.6
o
C, we used 81.0
o
C as we still had good PCR efficiency at 
this temperature. Indeed, Pritchard et al (2009) found that having Tc set to 
81.0
o
C increased the proportion of KRAS mutant alleles amplified in their serial 
dilution experiments.  
 
Table 15 Experimental determination of Tc from NSCLC adenocarcinoma A549 cell line for EGFR 
exon 21 an exon 19 and KRAS exon 2. 
Amplicon Tm 
(
o
C) 
Tc 
(
o
C) 
Temperature used for Step 6 
in PCR thermocycling (
o
C) 
EGFR Exon 19 86.4 85.6 85.6 
EGFR Exon 21 88.4 87.4 87.4 
KRAS Exon 2 82.6 81.6 81.0 
 
3.3.2 Confirmation by Agarose Gel Electrophoresis 
After the experimental determination of Tc, PCR thermocycling was carried out 
as described in 2.7.2 with the denaturation temperature in Step 6 set to the 
appropriate value for each of the exons as per Table 15. Following 
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thermocycling outlined in Table 6, the PCR products were electrophoresed on a 
2% (w/v) agarose gel to confirm amplification (Figures 13 - 15). 
 
Figure 13 COLD-PCR amplification of KRAS exon 2 from genomic DNA isolated from FFPE 
specimens (Lanes 2-6 and 7), N = No DNA, negative control.  Lane 1 = 100bp ladder.  
 
 
 
Figure 14 COLD-PCR amplification of EGFR exon 21 from genomic DNA isolated from FFPE 
specimens. Lane 1 = 100bp ladder.  
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Figure 15 COLD-PCR amplification of EGFR exon 19 from genomic DNA isolated from FFPE 
specimens (Lanes 2-7), N = no DNA, negative control. Lane 1 = 100bp ladder 
 
3.3.3 Conformation by DNA Sequencing 
After migration the COLD-PCR products were purified and sent to the 
Waikato DNA Sequencing facility for direct sequencing to determine if 
COLD-PCR could increase the sensitivity of direct sequencing, to enable the 
detection EGFR or KRAS mutations in the NSCLC FFPE specimens.  
The sequences obtained were entered into ‘Genebank’ and analysed in BLAST 
against the reference sequences for EGFR exon 21 and 19 and KRAS exon 2. 
Of the sequences obtained from the Waikato Sequencing Facility, none showed 
any misalignment that would be indicative of the LREA deletion, L858R or a 
codon 12 or 13 SNP. The sequence data for each of the respective exons from 
the FFPE specimens is presented in Table 24 in Appendix III. Indeed, this data 
was interpreted to determine the genotypes for the FFPE specimens, as 
according to the COLD-PCR and direct sequencing protocol, and presented in 
Table 16.  
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Table 16 Genotypes for the FFPE specimens as determined by COLD-PCR and direct sequencing  
Specimen  EGFR Exon 21 EGFR Exon 19 KRAS Exon 2 
24A6 WT WT WT 
54A4 WT WT WT 
98F7 WT WT WT 
77B4 WT WT WT 
34F3 WT WT WT 
19A8 WT WT WT 
WT = wild-type 
 
 
3.3.4 Conclusions 
Disagreeing with previous reports (Milbury, et al., 2009; Pritchard, et al., 2010; 
Yu et al., 2011), COLD-PCR was unable to increase the sensitivity of direct 
sequencing to detect EGFR and KRAS mutations in the NSCLC FFPE 
specimens. Indeed, while ‘clean’ electropherograms were obtained for each of 
the three exons for all of the FFPE specimens, the inability of this protocol to 
detect any EGFR or KRAS mutations was unexpected, given several previous 
reports of the success of this protocol in increasing the mutated (minor) allele 
frequency over the 20% that is required for mutation detection using direct 
sequencing.  
Interestingly, specimen 77B4, which was unable to be completely genotyped 
with our standard PCR and direct sequencing protocol, showed a wild-type 
sequence for EGFR exon 19 in the sequencing data generated using this 
COLD-PCR protocol. While it was expected that due to the asymmetric 
amplification of mutated alleles, this specimen would show a LREA mutation 
in EGFR exon 19, given the inherent heterogeneous nature of NSCLC 
adenocarcinomas, the genomic DNA used this protocol may not have 
contained sufficient mutated alleles, contributing to this result.  
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3.4 Restriction-digest mutant enrichment PCR  
Restriction-digest mutant enrichment PCR is a way of addressing inability of 
DNA Taq polymerase enzymes to selectively amplify mutant alleles. Indeed, by 
employing a restriction enzyme to selectively digest the wild-type sequences, the 
proportion of mutant alleles increases, thereby increasing the amplification of 
mutant alleles compared with wild-type alleles. This protocol was carried out as 
per Table 8 using the primers in 10. 
 
3.4.1 Conformation by PAGE Gel Electrophoresis 
The PCR products produced from the second round of PCR were 
electrophoresed on a 13% PAGE gel for restriction fragment length 
polymorphism analysis. Indeed, Figure 21 shows one of PAGE gel results of 
this protocol with EGFR exon 21. While two product bands can be seen 
between 300-400bp, this length does not correspond to the bp lengths from the 
primers as per Table 10. This result depicted in Figure 21 is typical of the 
results from this protocol with both EGFR exon 21 and exon 19, in that we 
were unable to produce results from which we could accurately genotype the 
NSCLC FFPE specimens. 
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Figure 16 Restriction-digest mutant enrichment PCR 12% PAGE gel from EGFR exon 21. Lane 2-5 = 
FFPE NSCLC specimens. Lane 1 = 100bp ladder. The product sizes seen between 300-400bp did not 
correspond to the product lengths expected from this protocol.   
 
3.4.2 Conclusions 
Given the results in Figure 16, this protocol was not able to genotype the NSCLC 
specimens, despite the significant modification and manipulation of the variables 
involved in our protocol outlined in 2.8. Indeed, the digestion incubation lengths, 
volumes, concentrations as well as the PCR thermocycling conditions were all 
extensively modified to no avail. As such, we concluded that despite the extensive 
investigation into the optimum conditions to achieve robust restriction digest 
mutant enrichment PCR mutation detection assay, we were not able to achieve a 
robust mutation detection assay using this protocol. 
  
300bp 
400bp 
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3.5 SSCP-PCR 
SSCP-PCR is a gel-based method that has been utilised for the detection of 
mutations in biopsy specimens for over a decade. Given that silver staining is 
approximately 100 times more sensitive than ethidium bromide, SSCP-PCR is 
considered to be a moderately sensitive protocol in that it has shown the ability to 
detect mutations in a considerable wild-type background. The SSCP protocol was 
carried out as per Table 5 using the primers in Table 4. 
 
3.5.1 Single Stranded Conformation Polymorphism 
The ssDNA products were electrophoresed on a 13% polyacrylamide gel, 
which was silver stained and the ssDNA banding patterns were compared to 
those produced the same way from the A549 NSCLC adenocarcinoma cell line. 
Given that the A549 cell line is known to be wild-type for EGFR, any FFPE 
specimens that showed aberrant banding compared to the A549 ssDNA, where 
considered indicative of the presence a mutation.  
Additionally, genomic DNA was also isolated from the area containing normal 
tissue from FFPE specimen 34F3 for KRAS comparison. This specimen was 
characterised by an experienced pathologist as containing mostly normal tissue 
and as a consequence made an ideal source of wild-type KRAS ssDNA for 
identifying KRAS mutation in the FFPE specimens. 
Indeed, the results of the SSCP-PAGE gel electrophoresis are depicted in 
Figures 17-21 for the respective exons.  
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Figure 17 SSCP 13% PAGE gel of EGFR exon 19. Left = wild-type A549 NSCLC adenocarcinoma cell 
line, Right = 34F3 FFPE NSCLC specimen. Banding pattern from the FFPE specimen is the equivalent 
to that seen from the A549 cell, indicating a wild-type sequence for EGFR exon 19 in this specimen. 
 
 
Figure 18 SSCP 13% PAGE gel from EGFR exon 19. Left = 54A4 FFPE specimen. Right = wild-type 
A549 NSCLC adenocarcinoma cell line. Banding pattern from the FFPE specimen shows an aberrant 
pattern compared to that of the A549 cell, indicating the presence of a mutation in EGFR exon 19 in 
this specimen.  
WT WT 
WT Mutant 
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Figure 19 SSCP 13% PAGE gel from EGFR exon 21. Left = wild-type A549 NSCLC adenocarcinoma 
cell line, Right = 54A4 FFPE NSCLC specimen. Banding pattern from the FFPE specimen is equivalent 
to that seen from the A549 cell, indicating a wild-type sequence for EGFR exon 21 in this specimen. 
 
 
Figure 20 SSCP 13% PAGE gel from EGFR exon 21. Left = A549 NSCLC adenocarcinoma cell line. 
Right = 98F7 FFPE NSCLC specimen. Banding pattern from the FFPE specimen shows an aberrant 
pattern compared to that of the A549 cell, indicating the presence of a mutation in EGFR exon 21 in 
this specimen. 
 
 
 
WT WT 
WT Mutant 
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Figure 21 SSCP 13% PAGE gel from KRAS exon 2. Left = specimen 77B4 , Right = 34F3 FFPE 
NSCLC. Banding pattern from the FFPE specimen is equivalent to that seen from the non-tumour 
genomic DNA isolated from the 34F3 FFPE specimen, indicating a wild-type sequence for the KRAS 
exon 2 in this specimen 
 
 
Table 17 Genotypes for the seven NSCLC FFPE specimens as determined by SSCP-PCR. 
Specimen  EGFR Exon 21 EGFR Exon 19 KRAS Exon 2 
24A6 WT Mutant WT 
54A4 WT Mutant WT 
98F7 Mutant WT WT 
77B4 WT WT WT 
34F3 WT WT WT 
4674 WT WT WT 
19A8 - - - 
WT = wild-type,     -   = unable to genotype. 
 
WT WT 
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3.5.2 Conclusions 
SSCP showed promising results as a number of differences in the appearance 
of bands were identified when comparing the FFPE specimens to those of the 
wild-type controls. Specifically, specimen 98F7 showed an aberrant pattern 
compared with the banding pattern produced from the A549 cell line for EGFR 
exon 21, while both specimen 24A6 and 54A4 showed an aberrant banding 
pattern compared with the banding pattern produced from the A549 cell line 
for EGFR exon 19. No mutations were detected in KRAS, however this was not 
unexpected given that FFPE specimens were selected to enrich for EGFR 
activating mutations and that mutations in KRAS are mutually exclusive to 
those in EGFR.  
However, while these bands indicate the presence of a mutation in these 
specimens, direct sequencing is still required to determine the exact position 
and type of mutation present. Moreover, this protocol was time-consuming in 
that it required considerable post-PCR processing and relied on a 4hour 
electrophoresis. Additionally, the inherent inconsistency in silver staining did 
confound judgement of mutation status of the specimens as there was 
variability from gel to gel.  
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3.6 DNA Melt Curves 
DNA melt curve analysis has recently been established as a rapid and sensitive 
method for moderate-throughput and cost-effective screening of mutations in 
clinical specimens. Indeed, DNA melt curve analysis has been applied to the 
detection of EGFR and KRAS mutations in a number of biological specimens.  
DNA melt curves were produced by heating the products produced from the 
protocol in Table 12 with the primers in Table 4, at 0.2
o
C/second. 
The resultant melt curves from 2.9.2 were compared to the melt curve produced in 
the same way from the NSCLC adenocarcinoma A549 cell line. As the mutation 
status of EGFR and KRAS is known for these cells, any melt curves produced that 
showed a left-shifted curve or skewed curves indicated the presence of a mutation. 
Indeed, the presence of a mutation in the specimen would result in the formation 
of heteroduplexes, which when compared to homoduplexes of the wild-type, 
would have lower melting temperature. This results a different melting activity 
which can be distinguished with the use of an intercalating fluorescent dye.  
As such, Figures 22-26 show the melt curves produced for the respective exons 
using both the A549 cells and the NSCLC FFPE specimens.  
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Figure 22 Melt Curve for EGFR exon 21 produced from the NSCLC adenocarcinoma A549 cell line. 
This cell line is known to be wild-type for EGFR activating mutations so was used as the control melt 
curve to which the NSCLC FFPE specimens were compared to.  
 
 
 
Figure 23 Melt Curve for EGFR exon 21 produced from the NSCLE FFPE specimen 98F7. The 
aberrant melt curve compared to the melt curve produced from the NSCLC adenocarcinoma A549 cell 
line was indicative of a mutation in EGFR exon 21 in this specimen. 
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Figure 24 Melt Curve for EGFR exon 19 produced from the NSCLC adenocarcinoma A549 cell line. 
This cell line is known to be wild-type for EGFR activating mutations so was used as the control melt 
curve to which the NSCLC FFPE specimens were compared to.  
 
 
 
Figure 25 Melt Curve for EGFR exon 19 produced from the NSCLC adenocarcinoma A549 cell line 
and FFPE specimen 54A4 (indicated with arrow). This cell line is known to be wild-type for EGFR 
activating mutations so the aberrant melt curve was indicative of a mutation in this NSCLC FFPE 
specimens were compared to. 
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Figure 26 Melt Curve for KRAS exon 2 produced from the normal tissue from the NSCLC FFPE 
specimen 34F3. All other NSCLC FFPE specimens showed the same melt curve profile which was 
indicative of a wild-type sequence for KRAS exon 2. 
 
 
Table 18 Genotypes for the seven NSCLC FFPE specimens as determined by DNA melt curve analysis 
Specimen  EGFR Exon 21 EGFR Exon 19 KRAS Exon 2 
24A6 WT Mutant WT 
54A4 WT Mutant WT 
98F7 Mutant WT WT 
77B4 WT WT WT 
34F3 WT WT WT 
4674 WT WT WT 
19A8 - - - 
WT = wild-type,     -   = unable to genotype. 
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3.7 Conclusions 
DNA melt curve analysis showed promising results as a number of differences 
in the melt curves were identified when comparing the FFPE specimens to 
those of the wild-type controls. Specifically, specimen 98F7 showed an 
aberrant melt curve compared with the wild-type melt curve produced from the 
A549 cell line for EGFR exon 21, while both specimen 24A6 and 54A4 
showed an aberrant melt curve when compared with the melt curve produced 
from the A549 cell line for EGFR exon 19. No mutations were detected in 
KRAS, however this was not unexpected, as previously mentioned, that FFPE 
specimens were selected to enrich for EGFR activating mutations and that 
mutations in KRAS are mutually exclusive to those in EGFR.  
While these melt curve indicate the presence of a mutation in these specimens, 
direct sequencing is still required to determine the exact position and type of 
mutation present. Moreover, in retrospect, using HRM with a green fluorescent 
dye such as Syto 13 would have been more applicable, given the greater 
resolution and therefore sensitivity of this protocol for mutation detection. 
 75 
 
3.8 Genotypes by Method 
Table 19 Summary of Genotypes for each of the FFPE specimens according to the different mutation detection protocols 
Specimen  Standard 
PCR 
COLD-PCR SSCP High Resolution DNA 
Melting Analysis 
Physical Characterisation 
of FFPE specimen 
24A6     Mostly tumour tissue 
     EGFR Exon 21 WT WT WT WT  
    EGFR Exon 19 WT WT Mutant Mutant  
   KRAS Exon 2 WT WT WT WT  
54A4     Mostly tumour tissue 
     EGFR Exon 21 WT WT WT WT  
    EGFR Exon 19 WT WT Mutant Mutant  
   KRAS Exon 2 WT WT WT WT  
98F7     All tumour tissue 
     EGFR Exon 21 WT WT Mutant Mutant  
    EGFR Exon 19 WT WT WT WT  
   KRAS Exon 2 WT WT WT WT  
77B4     Mostly tumour tissue 
     EGFR Exon 21 WT WT WT WT  
    EGFR Exon 19 ? WT WT WT  
   KRAS Exon 2 WT WT WT WT  
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34F3 Mostly normal tissue 
     EGFR Exon 21 WT WT WT WT  
    EGFR Exon 19 WT WT WT WT  
   KRAS Exon 2 WT WT WT WT  
19A8     Mostly tumour tissue –  
     EGFR Exon 21 ? WT - - very small specimen 
    EGFR Exon 19 ? WT - -  
   KRAS Exon 2 WT WT - -  
4674      
     EGFR Exon 21 # # WT WT Mostly tumour tissue 
    EGFR Exon 19 # # WT WT  
   KRAS Exon 2 # # WT WT  
? = inconclusive results,      -   =  unable to genotype       #   =  protocol was not carried out 
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3.9 Overall Conclusions 
Table 19 represents a summary of the genotypes established using each of the 
different mutation detection protocols for the seven NSCLC FFPE specimens used 
in this study. Overall, the sensitivity of these protocols was shown to be rather 
poor, as only SSCP and DNA melt curve analysis were able to detect putative 
mutations in the NSCLC FFPE specimens. Specifically, specimens 34F3 and 
54A4 were found to harbour an EGFR exon 19 mutation while specimen 98F7 
was found to harbour an EGFR exon 21 mutation. No mutations were detected in 
KRAS exon 2 in the six specimens used for this study. Given that these FFPE 
specimens were selected due to the possession of predisposing characteristics that 
would suggest they were likely to harbour mutant positive tumours, our EGFR 
mutation frequency was 43% (n=7), significantly higher than the reported 10% 
EGFR mutation frequency in the Western population.  
The two mutant allele enrichment protocols, COLD-PCR and restriction-digest 
mediated mutant enrichment PCR were implemented with no success. This was 
unexpected, however false negatives are well-reported given the heterogeneous 
nature of NSCLC specimens and the degraded DNA template. Also, given that we 
had such a high yield of genomic DNA from the FFPE specimens, the dilution of 
this DNA to 100ng/µL for use in PCR may have diluted the mutant concentration 
to levels below the enrichment capabilities of COLD-PCR and restriction-digest 
mediated mutant enrichment PCR.  
Of the FFPE specimens analysed in this study, 19A8 was particularly problematic 
as it was a very small specimen which contained a very small proportion of 
tumour tissue. The genomic DNA isolated from this specimen was minimal and 
also of relatively poor quality, which limited the inclusion of this specimen in the 
experimental work. Specifically, I was only able to genotype this specimen using 
Standard and COLD-PCR followed by direct sequencing due to the lack of DNA 
extracted from this specimen. As such, while these two protocols showed wild-
type sequences for both EGFR and KRAS genes, I would hesitate to conclude that 
this specimen does not harbour any mutations given the well-established false 
negative. Further, of the quality of the DNA isolated from this FFPE specimen 
was poor, which lead to a number of difficulties and consequently the failure to 
establish a definite genotype.  
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Additionally, unlike the other NSCLC FFPE specimens analysed in this study, 
specimen 4674 was analysed prospectively as this FFPE biopsy specimen was 
from a current patient and the genotype information elucidated in this study would 
be used to aid treatment regimen decisions. As such, only SSCP and DNA melt 
curve analysis were undertaken on this specimen as these mutation detection 
protocols were shown to have sufficient efficiency to detect EGFR mutations in 
other NSCLC FFPE specimens. Both these protocols found that this specimen was 
wild-type for both EGFR and KRAS, which was then reported back to the 
clinicians to aid their decision making.  
Finally, a number of specific conclusions can be made from the experimental 
work presented in this chapter: 
1. Incubation with mineral oil and SDS-lysis solution contributes to a high 
yield of quality genomic DNA from NSCLC FFPE specimens using a 
standard Proteinase K and phenol-chloroform extraction. 
2. A PCR buffer possessing a high magnesium concentration (4.5mM) is 
required to produce amplifiable products from FFPE NSCLC specimens in 
PCR. 
3. HOTFIRE Taq DNA polymerase is required for efficient amplification 
from NSCLC FFPE specimens. 
4. Standard PCR followed by Direct Sequencing was unable to detect any 
mutations in the NSCLC FFPE specimens analysed in this study. 
5. COLD-PCR followed by direct sequencing was unable to detect any 
mutations in the NSCLC FFPE specimens analysed in this study. 
6. Restriction-digest mediated mutant enrichment PCR involves an extensive 
and time consuming protocol that requires extensive optimisation and 
manipulation, which in our hands was unable to produce robust results 
from which we had the confidence to genotype the NSCLC FFPE 
specimens. 
7. SSCP-PCR is a mutation detection protocol that has sufficient sensitivity 
to detect EGFR mutations in NSCLC FFPE specimens. However, this 
protocol is labour intensive and has many confounding factors when trying 
to analyse results. 
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8. DNA melt curve analysis is a mutation detection protocol that has 
sufficient sensitivity to detect EGFR mutations in NSCLC FFPE 
specimens. This protocol relatively straightforward to implement as it is an 
in-tube i.e. non-gel based mutation detection technique.   
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4 Chapter 4   General Discussion 
 
Theoretically, the mutant DNA frequency in biological specimens, such as 
NSCLC FFPE specimens, is usually less than 5% of the wild-type DNA (Akagi et 
al., 2007). As a consequence, DNA sequencing may not detect the mutant DNA 
and more sensitive mutation detection techniques must be developed in order to 
detect mutations in this significant wild-type background. This study illustrates 
that the detection of EGFR and KRAS mutations in FFPE NSCLC specimens 
requires a highly sensitive and robust assay. Indeed, my results, combined with 
the experimental evidence of others (Beau-Faller et al., 2009; Hlinkova, et al., 
2011b; Krypuy, et al., 2006) have shown that direct sequencing, the ‘gold 
standard’ mutation detection technique, is sometimes unable to detect the 
mutation status of EGFR and KRAS genes in NSCLC FFPE specimens. 
Given the clinical significance of these biomarkers for predicting NSCLC patient 
response to EGFR-TKIs, significant work has been invested in the establishment 
of a more rapid, sensitive, accurate and cost-effective mutation detection assay. 
Accordingly, this study also investigated the sensitivity of several alternative 
PCR-based mutation detection protocols and found of these, SSCP and DNA melt 
analysis were able to detect EGFR mutations in NSCLC FFPE specimens. 
Although it is difficult to draw strong conclusions from such small sample 
numbers, this study also found that optimisation of thermocycling conditions is 
required to produce amplifiable products from FFPE NSCLC specimens. 
Further, while technical advancements such as COLD-PCR and restriction digest-
mediated mutant enrichment PCR can, through the asymmetric amplification of 
mutant alleles, theoretically increase the sensitivity of existing DNA analysis 
techniques, the application of these two protocols was limited in this study. 
Indeed, the inherent obstacles of FFPE NSCLC specimens, such as the highly 
heterogeneous nature of NSCLC tumours and the poor quality and quantity of the 
DNA template in these specimens present significant obstacles that must be 
overcome.  
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Moreover, while SSCP and DNA melt analysis can detect putative mutations in 
FFPE specimens one aspect that remains to be investigated is that conformation of 
such mutations by direct sequencing. Indeed, both these protocols can detect the 
presence of a mutation, but they do not provide information on the exact nature 
and position of the mutation identified. Given the poor sensitivity limit of direct 
sequencing, such identification is problematic (as shown in this study) as number 
of mutations can go undetected by direct sequencing. As such, while these 
methods enable the rapid screening of larger numbers of samples with increased 
sensitivity, they still require direct sequencing to confirm the clinical significance 
of the mutation, and further work is required for the establishment of a clinically 
relevant mutation detection protocol.  
In an attempt to develop such a protocol, alternative methods such as 
amplification refractory mutation systems (ARMS) combined with scorpion 
method and the peptide nucleic acid-locked (PNA) clamping method, are recently 
established methods that potentially could be used to rapidly detect rapidly EGFR 
and KRAS mutations using real-time PCR–based technology. However, without 
significant modification these protocols are not applicable in a clinical setting due 
to the high cost involved. For example the PNAClamp™ EGFR Mutation 
Detection Kit from Panagene costs US$ 3,750 for 25 tests (personal 
correspondence, 13/07/2011).  
Accordingly, despite significant effort, a routine clinical assay for EGFR and 
KRAS mutation detection has yet to be established. While some laboratories offer 
mutation testing of NSCLC patients, and commercially available kits are 
becoming readily available, these resources are not often applicable due to the 
high cost or inaccessibly of the majority of patients to such technology. Given this 
I investigated the use of direct sequencing, COLD-PCR, restriction-enzyme 
mediated mutation PCR, single stranded conformation polymorphism and high 
resolution melting analysis as clinically applicable EGFR and KRAS mutation 
detection assays in FFPE NSCLC specimens. This chapter will discuss the key 
results of this study and evaluate the sensitivity of the PCR-based mutation 
detection protocols and their suitability for inclusion in clinical practice. 
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4.1 Isolation of genomic DNA from FFPE Specimens 
DNA analysis protocols are dependent on the careful extraction and purification 
of DNA from FFPE specimens. Consequently, several methods have been 
established for the extraction of DNA from FFPE specimens and commercial kits 
are becoming readily available (Miyamae, et al., 2010). However, these extraction 
methods often require extensive and time consuming protocols which complicate 
the isolation of quality DNA and limit their inclusion in routine clinical testing 
(Okello et al., 2010). 
DNA extraction and isolation from FFPE specimens is particularly problematic as 
formalin, whilst an excellent preserver of the integrity of the tissues, compromises 
the DNA quality, by not only causing the DNA to become fragmented, but also 
facilitating the formation of cross-links between nucleic acids and proteins. This 
tends to result in DNA species with average base pair lengths of approximately 
200-300bp (Hongdo Do & Dobrovic, 2009). Additionally, the paraffin-embedding 
process and subsequent storage lead to nucleic acid degradation and modification 
which further diminish the quality and yield of DNA within these specimens. 
To address the problems associated with the extraction of genomic DNA from 
FFPE specimens, I employed a method adapted from Lin et al. (2009) with 
considerable success. Specifically, this method utilised mineral oil to 
deparaffinise the FFPE specimens and incubation with a high pH lysis solution to 
increase the yield of genomic DNA. After which, the specimen was subjected to a 
standard extraction method involving Proteinase K and phenol-chloroform. 
Indeed, the DNA yield from all but one FFPE specimen was significantly higher 
than anticipated, and in particular, the 260/280 ratios for these specimens were 
surprisingly close to ideal (as shown in Table 13). Given the low cost and toxicity 
associated with mineral oil, I concluded that it provides an ideal reagent to extract 
high yields of quality genomic DNA from FFPE specimens in routine clinical use 
(J. Lin et al., 2009).  
4.2 PCR failure with FFPE DNA template 
Most DNA analysis protocols are PCR based and the robust amplification of 
the genomic DNA isolated from FFPE specimens is crucial for the success of 
the downstream mutation detection protocol. However, PCR failure is of 
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particular concern when dealing with FFPE specimens due the chemical 
processes involved in the fixation and storage process that cause damage to the 
DNA often resulting in failed reactions (Miyamae, et al., 2010). Indeed, this 
damage reduces the amplification strength of DNA polymerase enzymes as 
they often encounter ‘blocks’ along the FFPE DNA template. Additionally, the 
miss-incorporation of nucleotides is common with a degraded DNA template, 
which further reduces the efficiency of amplification, as the enzyme must then 
replace this via its proofreading and exonuclease activity.    
As such, a number of research groups have reported difficulties in working 
with FFPE specimens, with some even going as far as to suggest that some of 
the novel variant mutations reported by have been artificially induced by 
working with small amounts of damaged DNA (Farrugia, et al., 2010). Given 
that PCR amplification strength from FFPE specimens is adversely related to 
product size, a typical molecular behaviour of degraded DNA, there is 
considerable risk associated with the use of DNA isolated from FFPE 
specimens for mutation detection due to the significant risk of indeterminate or 
false-negative results (Takano, et al., 2007). 
 
4.2.1 Optimisation of PCR thermocycling conditions 
Given the poor amplification ability of DNA isolated from FFPE specimens, 
significant time and labour went into the optimisation of PCR conditions to not 
only avoid PCR failure, but also to increase the efficiency of amplification 
from the FFPE NSCLC specimens. However, despite this considerable effort 
that went into the optimisation of PCR conditions (as discussed further below), 
I found that this was not able to overcome the poor sensitivity of direct 
sequencing.  
Significantly, I found that amplification from the A549 NSCLC 
adenocarcinoma cell line did not require the same optimisation processes, as 
robust amplification was achieved from the genomic DNA isolated from these 
cells in thermocycling conditions that were not able to produce amplification 
products from the FFPE NSCLC specimens.  This was not unexpected since 
the DNA should not be degraded in these cells.  
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4.2.1.1 Primer design 
It has been well documented that extraction from FFPE specimens tends to 
result in DNA fragments with the average base pair length of 200-300bp 
(Okello, et al., 2010). In attempt to ensure robust amplification from the FFPE 
specimens, primers which resulted in amplicon lengths of less than 300bp were 
selected. Indeed, the resultant PCR products produced from these primers was 
of suitable length to minimise the adverse effects of formaldehyde on the DNA 
within the FFPE specimens, and I was able to reproducibly produce 
amplification products for EGFR exon 21 and 19 and KRAS exon 2 from all 
seven specimens.  
The primers selected had binding sites within the intro-exon boundary, 
increasing the likelihood of mutation detection within the exon, as direct 
sequencing often fails to correctly identify the nucleotides at the ends of the 
PCR product sequences. Indeed, upon close analysis of the electropherograms, 
significant background signal could be seen in the beginning and end of all the 
sequences obtained. Due to this poor signal-to-noise ratio, this part of the 
sequencing data was removed before BLAST analysis to ensure alignments 
with the mutation hotspot in the exon.  
Moreover, primer selection was also important to ensure the robust nature of 
the downstream DNA analysis, particularly with SSCP and DNA melt analysis. 
These two protocols are susceptible to single nucleotide polymorphism (SNP) 
interference, as they are unable to distinguish between the presence of SNP and 
a mutation of interest. As such, primers that produced amplification products of 
approximately 200bp and flanked the exons as closely as possible were 
selected to reduce the chance of SNP interference confounding results from 
these protocols.  
 
4.2.1.2 Magnesium Concentration 
Magnesium (Mg
2+
) is an essential ingredient that stabilises the interactions 
between the oligonucleotide primers, template DNA and Taq DNA polymerase 
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enzyme. Given that Mg
2+
 is a co-factor for the Taq DNA polymerase enzyme 
the Mg
2+
 concentration can greatly affect the efficiency of amplification in 
PCR. Specifically, it has been shown that an excessive magnesium 
concentration can cause mis-priming, in that primers bind to incorrect template 
sites resulting in non-specific products. Insufficient magnesium leads to an 
inefficient DNA product yield, or in some cases, no production of products at 
all (Evans, 2009). 
While 1.5mM is the standard Mg
2+
 concentration used for most PCR 
thermocycling, a higher concentration can increase PCR specificity and 
efficiency (Evans, 2009). Given the poor quality of the template DNA in these 
experiments, increasing the magnesium was hypothesised to increase the 
efficiency of amplification, due to the use of a high fidelity Taq enzyme with 
proofreading and exonuclease activity.  Indeed, my experiments showed the 
manipulation of the Mg
2+
 concentration can greatly affect the efficiency of 
PCR amplification from DNA isolated from FFPE specimens. Specifically, the 
use of a higher concentration of magnesium (4.5mM) was much more efficient 
than the standard magnesium concentration of 1.5mM in the production of 
PCR products from our FFPE specimens. As such, while the standard 
magnesium concentration was sufficient to produce products from the A549 
NSCLC cell line, it was unable to reproducibility produce products from the 
FFPE specimens.  
 
4.2.1.3 High fidelity DNA Taq Polymerase Enzyme 
The adverse effects of formalin on the quality of DNA in FFPE specimens are 
well documented and known to be the source of PCR artefacts. Indeed, when 
Taq DNA polymerase encounters damaged templates it has the propensity to 
stop nucleotide incorporation and to insert a non-complementary residue 
(usually an adenosine) into the stand being synthesised (Evans, 2009). As such, 
a variety of polymerase-mediated sequence changes can occur during PCR 
amplification, including single base substitutions, deletions and insertions. Of 
these, single base substitutions that result from the misincorporation of 
incorrect dNTPs are the most common type of artefactual change (Hongdo Do 
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& Dobrovic, 2009). This often leads to false positives, as the downstream DNA 
analysis will detect a change in the DNA sequence and not attribute this to an 
experimental artefact. 
Several researchers have suggested that the detection of mutations, in particular 
novel variants, in genomic DNA isolated from FFPE specimens is the result of 
dealing with small quantities of suboptimal quality DNA (J. Lin, et al., 2009). 
Indeed, more frequent DNA polymerase errors have been detected with direct 
sequencing when amplifying from FFPE specimens than the matched fresh 
frozen tissues, highlighting the artificial sequence changes that occur as a result 
of DNA polymerase error and/or damaged DNA templates (Siwoski, et al., 
2002). Do et al. (2009) compared HRM and direct sequencing in FFPE 
specimens and peripheral blood and while they reported several PCR artefacts 
with the FFPE specimens, they encountered none with the DNA isolated from 
the peripheral blood. Additionally, they also investigated if these PCR artefacts 
they saw in FFPE specimens were caused by DNA polymerase error or 
chemical damage to the genomic DNA by using two DNA polymerases having 
different degrees of fidelity. Consequently, they found that PCR artefacts were 
not reduced as a result of increasing the fidelity of DNA polymerase, leading 
them to conclude that the damaged DNA template is likely to be the cause of 
PCR artefacts 
As part of this study I investigated the use of two DNA polymerase enzymes 
and found that HOTFIRE DNA Taq Polymerase was required for the robust 
amplification from genomic DNA isolated from our FFPE specimens. Given 
that DNA polymerase is a magnesium dependent enzyme, the synergy between 
the high magnesium buffer concentration and HOTFIRE Taq DNA polymerase 
could have contributed the increased efficiency of amplification from the FFPE 
specimens and thus this result.  
 
4.3 Direct Sequencing 
As previously mentioned, direct sequencing is considered the ‘gold standard’ 
mutation detection technique however it requires a sufficient amount of tumour 
tissue of relatively good quality, which is difficult to obtain from NSCLC patients 
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with inoperable tumours (Do et al 2008). Specifically, it has been shown that the 
accuracy of this protocol is limited if the biopsy material available contains less 
than 60% tumour cells (van Zandwijk, et al., 2007). Given that NSCLC specimens 
often only contain between 2-50% tumour tissue, it has been suggested that most 
mutations in NSCLC FFPE specimens cannot be detected by direct sequencing 
(Miyamae, et al., 2010). 
Indeed, the low amount of tumour tissue, combined with the inherent 
heterogeneous nature of NSCLC tumours means that clinically significant somatic 
mutations such as those in EGFR and KRAS genes are present at frequencies 
lower than 25% (given that humans are diploid and oncogenic mutations are often 
heterozygous). Accordingly, experimental evidence is accumulating that the use 
of direct sequencing for mutation detection in FFPE specimens results in a 
number of false negatives, particularly when compared with more sensitive 
mutation detection techniques (Asano, et al., 2006; Heideman et al., 2009) 
(discussed further in subsequent sections).  
Moreover, due the artificial sequences changes as a result of DNA polymerase 
error and the degraded FFPE template, the false positive rate of mutation 
detection with standard PCR and direct sequencing has been established to be 
approximately 16% in DNA derived from FFPE specimens (Fadhil, Ibrahem, 
Seth, & Ilyas, 2010). Consequently, there is significant experimental evidence, 
including the results presented in this study, that highlight the need for the 
development of alternative protocols which are able to genotype NSCLC FFPE 
specimens which typically harbour low frequencies of mutated alleles with higher 
accuracy, selectivity and sensitivity. Additionally, given the high cost, 
requirement of specialised equipment and the time consuming nature of direct 
sequencing, there is significant need to develop protocols which are not only more 
sensitive, but also cost effective, faster and easier to perform, for routine testing to 
become part of clinical practice.    
 
4.4 COLD-PCR 
COLD-PCR is a new form of PCR that has been developed to enrich the 
mutation-containing alleles through changing the denaturation temperature during 
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PCR. Indeed, through changing a single parameter of thermocycling, COLD-PCR 
provides an ideal and simple protocol to increase the sensitivity of PCR-based 
mutation detection assays (Milbury, et al., 2009).  While the COLD-PCR protocol 
has been used for mutation detection in colorectal and pancreatic cancers 
(Pritchard, et al., 2010; Yu, et al., 2011), it has not, to my knowledge, been 
applied to mutation detection in NSCLC. 
The application of COLD-PCR to the amplification of low-level EGFR and KRAS 
somatic mutations in NSCLC specimens could provide an accurate, convenient 
and cost-effective way to address the sensitivity and selectivity of PCR-based 
DNA analysis assays. There are two forms of COLD-PCR, fast COLD-PCR and 
full COLD-PCR which differ in terms of their duration and mutation enrichment 
capabilities. Full COLD-PCR takes much longer (approximately 8hours) but is 
able to detect mutations irrelevant of whether they are known or unknown or what 
type of mutation they are (transversions or transitions). While, fast COLD-PCR 
takes considerably less time, it is only able to detect known mutations and 
struggles to detect transitions as these only result in a small change in melting 
temperature (Pritchard, et al., 2010).  
The decreased denaturation temperature of COLD-PCR causes the preferential 
denaturation of heteroduplexes (formed by hybridisation of mutant and wild-type 
sequences), and thus enriches mutated allele frequency. As such, COLD-PCR has 
been reported to increase mutant allelic concentrations sufficient for accurate 
genotyping via direct sequencing and other mutation detection protocols (Milbury, 
et al., 2009; Pritchard, et al., 2010; Yu, et al., 2011).  
Yu et al. (2011) investigated the use of COLD-PCR to detect KRAS mutations in 
29 FFPE pancreatic specimens and compared the results with those of standard 
PCR. Significantly, they found that direct sequencing following standard PCR 
was only able to detect 11 (37.9%) KRAS mutations, while COLD-PCR-mediated 
direct sequencing detected 21 mutations (72.44%). They also used dilution 
experiments, whereby they mixed a known concentration of KRAS mutant alleles 
in a background of wild-type alleles, to show that mutation detection with direct 
sequencing following COLD-PCR has an approximate 5-fold improvement 
compared with standard PCR.  
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Pritchard et al. (2010) compared direct sequencing following both standard PCR 
and COLD-PCR, and HRM analysis following standard PCR and COLD-PCR for 
the detection of KRAS mutations in 61 FFPE colorectal cancer specimens. Of 
these 61 specimens, they found that all protocols detected KRAS mutations in 29 
specimens; however, COLD-PCR increased the sensitivity of both HRM analysis 
and direct sequencing, in that COLD-PCR enhanced HRM and sequencing 
detected an additional 4 specimens harbouring KRAS mutant tumours.  
As such, this experimental evidence would suggest that COLD-PCR increases the 
sensitivity of PCR-based assays to enable accurate detection of low-level 
mutations such as those present in EGFR and KRAS in FFPE NSCLC specimens. 
However, in my hands this protocol, while relatively straightforward, was unable 
to overcome the sensitivity limit of direct sequencing. Indeed, I was unable to 
detect any EGFR or KRAS mutations in our FFPE specimens at all using this 
protocol, while I was able to detect putative mutations in both SSCP and DNA 
melt analysis.  
 
4.5 Restriction-enzyme mediated mutant enrichment PCR 
Like COLD-PCR, the restriction-enzyme mediated mutant enrichment PCR assay 
is another protocol that has been established to enrich mutation-containing alleles 
to levels to enable their detection in significant wild-type background. 
Specifically, through selection of restriction enzymes with recognition sites 
exclusively present in the wild-type sequence, the mutant-enriched PCR assay is 
able to increase the proportion of mutant alleles present in a heterogeneous 
sample. Thus, during thermocycling mutant alleles will be selectively amplified, 
contributing to an increase in the sensitivity of downstream mutation detection. 
Indeed, the use of restriction enzymes to increase low level EGFR and KRAS 
mutations has been applied in a number of biological specimens with success. 
Specifically, Asano et al (2006) analysed the mutation status of EGFR in 
surgically resected specimens from 108 NSCLC patients using a mutant-enriched 
PCR assay and compared the results with direct sequencing and non-enriched 
PCR assay. They found that the mutant-enriched assay was able to detect EGFR 
mutations in 37 patients, whereas direct sequencing was only able to detect 16 
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mutations. Given the increased sensitivity of this assay, they concluded that they 
had developed a highly sensitive mutation detection assay that could be used on 
clinical samples.  
Additionally, Hlinkova et al (2011) analysed 53 archival cytologic specimens that 
were fixed with methanol and stained with Giemsa or Papanicolaou staining using 
the same mutant-enrichment protocol developed by Asano et al, to enhance direct 
sequencing and HRM. They found that direct sequencing was only able to detect 
five of the 13 EGFR mutations identified by HRM. However, when the used 
mutant-enrichment assay prior to sequencing, all 13 EGFR mutations could be 
detected using this protocol.  
Given the previous experimental results highlighting the sensitivity of this 
protocol to detect EGFR mutation in NSCLC patients in a variety of biological 
tissues, it was hypothesised that it would offer a relatively sensitive and robust 
mutation detection assay for the use on the FFPE NSCLC specimens used in this 
study. However, despite significant experimental work, I had very limited success 
with this protocol, as no robust results could be obtained from our FFPE 
specimens.   
Indeed, significant modification and time-consuming experimental work was 
carried out to ascertain the optimum conditions to achieve a robust assay, yet I 
was unsuccessful in elucidating these parameters. The restriction digest incubation 
often resulted in the ‘shearing’ of the DNA, that when visualised on an agarose 
gel, appeared as a giant smear from the well. Conditions for the restriction digest 
were extensively manipulated, including time, volume, units of enzyme, 
restriction enzyme buffer volume, BSA concentration, DNA template 
concentration, yet none of the changes we made to these parameters could 
establish results with which we could genotype the FFPE specimens.  
Given that we used a very similar protocol to both Hlinkova et al and Asano et al, 
the failure of this protocol was unexpected. However, Asano et al only used 
computed tomography-guided needle lung biopsies, pleural fluid and surgically 
resected specimens and Hliknova et al used archival cytologic specimens that 
were fixed with methanol and stained with Giemsa or Papanicolaou staining. 
Given the previously described complications as a result of the chemical 
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processes involved in FFPE biological specimens, I would question if the nature 
of the genomic DNA isolated from the FFPE NSCLC specimens used in this 
study was not applicable to this protocol. 
As such, I was not able to establish a robust mutant-enrichment protocol, as I had 
a significant amount of no-results during the experimental work, where the 
restriction enzymes caused the ‘shredding’ of the DNA, and smears (no specific 
bands) were seen when the PCR products were electrophoresed. Additionally, the 
few times that I was able to produce amplification product there was a significant 
amount of post-PCR processing involved. Given that this protocol does rely on 
two rounds of PCR, a restriction digest and the subsequent electrophoresis on a 
polyacrylamide gel, the rather complex nature of this protocol is not applicable to 
a high throughput that would be require for it to be applied in clinical practice.    
 
4.6 Single-stranded Conformation Polymorphism 
SSCP relies in the principle that the electrophoretic mobility of a ssDNA molecule 
is highly dependent on its size and structure (Hu, et al., 2007). Given that the 
ssDNA molecules take up conformations based on their underlying DNA 
sequence, a mutation at a particular nucleotide position will alter this 
conformation and hence its migration in a gel. As a consequence, when 
electrophoresed on a gel matrix, molecules that differ, even as little as a single 
nucleotide can be distinguished.  
Due to the relative simplicity of this protocol, SSCP has been applied to mutation 
detection in many contexts, including the detection of EGFR and KRAS mutations 
in biological specimens. Indeed, Sarkak et al (1995) investigated the use of SSCP 
to detect KRAS mutations in frozen and FFPE tumour specimens of 55 NSCLC 
patients. They detected 10 of the 55 patients (18%) to have KRAS mutations in 
both frozen and FFPE specimens. 
Additionally, Marchetti et al (2005) analysed the tumour and matched normal 
tissue of 375 NSCLC patients using both SSCP-PCR and direct sequencing. 
Specimens were taken macroscopically, snap-frozen in liquid nitrogen and stored 
at -80
o
C. Using both protocols they found 31 EGFR mutations (8%) in the tumour 
tissue, while no mutations were found in the normal tissue. Indeed, while direct 
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sequencing could detect EGFR mutations in 31 patients, SSCP analysis confirmed 
these and found an additional eight mutations: seven in exon 21 and one in exon 
18.  
As such, experimental evidence has led to the conclusion that SSCP-PCR is more 
sensitive than direct sequencing and can be performed on biological samples, 
including FFPE specimens, with considerable success (Marchetti et al., 2005; 
Sarkar et al., 1995). Further, it has also been reported that SSCP requires as little 
as 10% mutated DNA to detect mutations, which is considerably less than the 
20% required by direct sequencing. In accordance with this, I also found that 
SSCP-PCR was a highly sensitive protocol in that it was able to detect EGFR 
mutations in the NSCLC FFPE specimens used in this study. I found that two 
specimens 24A6 and 54A4 harboured exon 19 mutations, while specimen 98F7 
harboured an exon 21 mutation.  
However, while SSCP is more sensitive than direct sequencing, it does require 
significant post-PCR processing. As such, the production of ssDNA molecules 
from the PCR products, the lengthy electrophoresis in combination with the 
labour intensive silver staining procedure, contribute to a significant turn-around 
time. Given the inherent variability in this process, along with the significant time 
it takes to obtain results, this protocol is not applicable to clinical practice, given 
the need for both a high-throughput and rapid turnaround time to aid physician’s 
decision making.  
Moreover, since the development of next generation technologies, the reported 
accuracy of SSCP has since been shown to vary between 60-90% and is highly 
dependent on several factors that need to be optimised for each area of interest 
(REF). Moreover, the detection sensitivity decreases further when amplicon 
length is longer than 200bp, which is smaller than the exons in EGFR (Weber, 
Fukino, Villalona-Calero, & Eng, 2005).  
As such, while I have found that this protocol is highly sensitive, there are many 
aspects of this protocol that make it impractical for application to clinical practice. 
Given this, further work must be done to establish a protocol that is less time 
consuming, and requires less post-PCR processing to obtain the same sensitivity 
and selectivity to detect EGFR and KRAS mutations in FFPE NSCLC specimens. 
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4.7 DNA melt analysis and High Resolution DNA melting analysis 
Since it was introduced in 2002, HRM has had widespread application to 
genotyping, mutation scanning and sequence matching (Reed, et al., 2007). As 
such, HRM analysis is expected to be one of the most practical methods for 
detecting EGFR and KRAS mutations in clinical practice. HRM is of particular 
advantage as it is a closed-tube design whereby an intercalating fluorescent dye is 
incorporated, without affecting efficiency, during PCR thermocycling. 
Amplification is immediately followed by the monitoring the change of 
fluorescence as the intercalating fluorescent dye is released, as the DNA duplexes 
are slowly heated causing the separation of the two strands (Tindall, Petersen, 
Woodbridge, Schipany, & Hayes, 2009). 
It should be noted that the Corbett instrument used in this study was unable to 
undertake HRM analysis as this requires the instrument to acquire on the green 
channel which requires a specific green fluorescent dye such as Syto 13. Indeed, 
while our protocol was able to detect mutations in the NSCLC analysed, the use 
of HRM is likely to be more sensitive, and such an area of further research.  
One of the major advantages of HRM is that unlike most DNA analysis 
techniques, no post-PCR processing is required (Reed, et al., 2007). Given that all 
the previously described protocols require the use of gel-based methods, they are 
both time consuming and difficult to optimise. As such, in-tube i.e. non-gel 
protocols such as HRMA are becoming increasing important to increase the 
simplicity and turnaround time, without comprising sensitivity and accuracy, for 
the translation of genetic information in clinical practice. Indeed, HRM analysis 
has been shown to be a highly sensitive non-sequencing method to detect EGFR 
and KRAS mutations in a significant wild-type background, such as in FFPE 
NSCLC specimens. 
Takano et al (2007) investigated the use of HRM analysis to detect EGFR 
mutations in 207 NSCLC patients. They also carried out direct sequencing to 
validate HRM against the ‘gold standard’ mutation detection method. The DNA 
extracted from FFPE or Papanicolau-stained cytologic specimens was subjected to 
PCR followed immediately by HRM. The melt curves produced from these 
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specimens were compared to genomic human DNA, which was used as a control 
sample to generate melting curves for EGFR WT. Those samples that showed 
skewed or left-shifted curves from the control samples were judged to have a 
mutation. They found the sensitivity of HRM analysis using DNA extracted from 
FFPE specimens was 92% and the specificity was 100%, which was significantly 
higher than direct sequencing. Specifically, EGFR exon 19 mutations were 
detected in 49 (24%) patients and EGFR exon 21 mutations were detected in 36 
(17%) patients, while the other 122 (59%) were considered to be wild-type.  
Additionally, Nomoto et al (2006) used HRMA to detect EGFR exon 19 deletions 
and L858R mutations in archival Papanicolau-stained cytologic specimens from 
29 NSCLC patients. They identified EGFR mutations in 19 samples and wild-type 
EGFR in 15 samples accurately by HRM analysis, but two samples gave false-
negative results and one was indeterminate. As such, the sensitivity of HRM 
analysis was 88%, while the selectivity was 100%. They also conducted 
sensitivity studies using 3 adenocarcinoma cell lines, H1650 (delE746-A750), 
H1975 (L858R mutation) and A549 (WT EGFR). Dilutions of EGFR mutant 
cells, H1650 and H1975, where done by using proportions of A549 cells ranging 
from 100% (no A549 cells) to 0% (no mutant cells). These dilution experiments 
showed that HRM analysis could detect both EGFR exon 21 and exon 19 
mutations if at least 10% of cells in a sample where mutants.   
Further, Krypuy et al. (2006) investigated the use of HRM analysis to screen 30 
NSCLC patients for KRAS mutations. Using this protocol they found that 9 of the 
30 NSCLC biopsies had KRAS mutations and these mutations could also be 
detected by direct sequencing. They also validated the sensitivity of HRM 
analysis using dilution experiments, and found that HRM analysis could detect 
KRAS mutations present as low as 6% in wild-type background.  
Finally, Farral et al. (2009) combined 19 studies and found the HRM had an 
overall sensitivity 99.3% (n= 839) and specificity 98.8% (n = 2659).  As such, 
HRM analysis has been shown great efficacy in identifying mutations with less 
labour, time and expense. Indeed, PCR and melting analysis can be carried out in 
the same tube within a few hours, and the running cost has been reported to be as 
low as approximately 1 U.S. dollar per sample (Takano, et al., 2007). HRM 
analysis enables the high throughput screening of gene mutations, which can 
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provide clinicians with timely information to aid the selection of appropriate 
therapeutic choices.  
Given the experimental evidence of others, as well as the information presented in 
this study has highlighted the aptness of analysing the melting behaviour of DNA 
sequences as a mutation detection technique. Indeed, in my hands DNA melt 
curve analysis was a highly sensitive protocol in that it was able to detect EGFR 
mutations in the NSCLC FFPE specimens used in this study. Specifically, I found 
that two specimens 24A6 and 54A4 harboured exon 19 mutations, while specimen 
98F7 harboured an exon 21 mutation. As such, I would conclude that the use of 
DNA melt curve analysis or more specifically, the use of the more sensitive HRM 
analysis would be an ideal mutation detection protocol to be included in routine 
clinical practice. 
 
4.8 Clinical implications of developing an assay to detect the mutation 
status of EGFR and KRAS genes in NSCLC patients 
The mutation status of EGFR and KRAS is highly predictive of patient response, 
or lack thereof respectively, to EGFR-TKIs, which have been introduced for the 
treatment of advanced NSCLC. As such, the development of a clinically relevant 
assay to detect the mutation status of these two oncogenes in FFPE specimens is 
crucial for the establishment of personalised medicine in the treatment of NSCLC 
to ultimately improve patient outcomes and address the poor survival rate 
associated with the disease. 
Currently, aspects such as cost, turnaround time, and quality management are 
unfavourable with the mutation detection protocols employed. However, the 
advent of next generation molecular tools provides promising protocols with 
greater sensitivity, accuracy, precision and selectivity for mutation detection. As 
such, a clinically relevant mutation detection assay must be easy to apply, rapid, 
cost-effective, and applicable to small amounts of biopic material and not require 
extensive labour or sophisticated equipment for the translation of personalised 
medicine into clinical practice.  
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Given the inherent obstacles of NSCLC FFPE specimens, further work is required 
to establish a clinically relevant mutation detection protocol in these patients. As 
such, while SSCP-PCR and DNA melt curve analysis can detect putative 
mutations in NSCLC FFPE specimens, the widespread application of these 
protocols to detect mutations to aid therapeutic treatment decisions is limited. 
Indeed, I would suggest that until samples from patients are taken specifically for 
use in genetic testing, the application of personalised medicine in NSCLC is 
unlikely to occur in clinical practice. 
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       Appendix I 
 
This table represents the known EGFR mutations, most of which are present at 
such a low frequency that their clinical significance is yet to be established. 
Table 20 EGFR mutations in NSCLC. *Clinically significant mutations 
Exon Mutation 
type 
Nucleotide change Amino acid change 
18 missense c.2126A>C p.E709A 
  c.2155G>A p.G719S 
  c.2156G>C p.G719A 
  c.2170G>A p.G724S 
 del/insertion c.2127_2130del4insC p.E709_T710delinsD 
19 del/insertion c.2233_2245del15 p.K745_D749del 
  c.2235_2249del15* p.E746_A750del* 
  c.2235_2249del15insTTC p.E746_A750delinsF 
  c.2236_2250del15 p.E746_A750del 
  c.2237_2251del15 p.E746_A750del 
  c.2237_22512del16insT p.E746_A750delinsV 
  c.2237_2238ins18 p.E746VinsPVAIKE 
  c.2239_2248del10insC p.L747_D749delinsP 
  c.2239_2251del13insC p.L747_T751delinsP 
  c.2239_2258del20insCA p.L747_P753delinsQ 
  c.2240_2254del15 p.L747_T751del 
  c.2240_2257del18 p.L747_P753delinsS 
  c.2252_2276del25insA p.T751_I759delinsN 
20 missense c.2303G>T p.S768I 
 del/insertion c.2300_2308del9 p.A767_V769del 
  c.2309_2310insCCAGCGTGG p.D770_H773insGSV
D 
  c.2311A>G, 
2312_2313insGGT 
p.N771_P772insGY 
  c.2317delCinsTACAACCCCT p.H773_R776insYNP
Y 
  c.2322_2323insCCACGT p.C775_R776insPA 
 silent mutation c.2289C>T p.A763A 
  c.2313C>T p.N771N 
21 missense c.2506C>T p.R836C 
  c.2573T>G* p.L858R* 
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                                                                                  Appendix II 
Table 21 List of trial abbreviations, definitions and description with trial outcome  
Trial 
Abbreviation 
Trial Definition Description Outcome Reference 
IDEAL  Iressa Dose Evaluation in 
Advanced Lung Cancer 
Phase II clinical trial 210 patients with advanced 
NSCLC randomised to receive different doses of 
gefitinib  
Similar efficacy in response rates, PFS and 
OS in both groups 
(Ansari, et al., 2009) 
INSTANA IRESSA as Second-line 
Therapy in Advanced NSCLC 
- KoreA 
Phase III 1217 Asian non-smoking patients with 
advanced NSCLC randomised to receive 
gefitinib or carboplatin and paclitaxel 
Superior PFS for gefitinib compared with 
combination of carboplatin and paclitaxel 
(C.-C. Lin & Yang, 
2011) 
INTACT Iressa NSCLC Trials 
Assessing Combination 
Therapy 
Phase III trial involving 1093 patients who 
received gefitinib and chemotherapy or 
chemotherapy alone. 
No increase in survival benefit or 
improvement in response for combination 
therapy 
(Ansari, et al., 2009; 
C.-C. Lin & Yang, 
2011) 
INTEREST Iressa NSCLC Trials 
Evaluating Response and 
Survival versus Taxotere  
Phase III trial with 1433  patients who had 
already received chemotherapy randomised to 
receive gefitinib or docetaxel 
Increased overall survival in those patients 
receiving gefitinib but no significant 
difference in progression free survival. Sub-
analysis of EGFR mutation positive patients 
showed increased PFS and response rates 
with gefitinib vs docetaxel. 
(Cataldo, et al., 2011; 
C.-C. Lin & Yang, 
2011) 
IPASS Iressa Pan-Asia Study Randomised Phase III trial in Asia with non-
smokers who received either gefitinib or 
chemotherapy with carboplatin and paclitaxel.  
PFS at one year was significantly greater in 
those patients who received gefitinib (24.9% 
vs. 6.7%). OS similar in both groups but 
improvement in the quality of life in those 
receiving gefitinib.  
(Cataldo, et al., 2011; 
Ma, Hui, & Mok, 
2010; Mitsudomi, 
2010)  
ISEL Iressa Survival Evaluation in 1692 patients with advanced NSCLC and prior Compared with placebo, gefitinib had Hann et al, (Masago, et 
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advanced Lung cancer chemotherapy therapy were randomised to 
receive gefitinib or placebo. 
higher response rates (8.0% vs. 1.3%) but 
no change in survival benefit. Sub-analysis 
of non-smokers treated with gefitinib 
showed increased survival (8.9months vs. 
6.1months with placebo. 
al., 2008) (Wu, et al., 
2010) (C.-C. Lin & 
Yang, 2011; Provencio, 
et al., 2009) 
TALENT Tarceva Lung Cancer 
Investigation Trial 
Phase III involving 1172 patients who received 
chemotherapy with erlotinib or chemotherapy 
alone  
Adding erlotinib to chemotherapy did not 
increase overall survival  
(C.-C. Lin & Yang, 
2011) 
TRIBUTE Tarceva Responses in 
Conjunction with Paclitaxel 
and Carboplatin 
Randomised allocation of chemotherapy, placebo 
and erlotinib in 116 patients 
After chemotherapy no significant 
differences were found between smokers 
and non-smokers in response or overall 
survival. The sub-group of non-smokers 
treated with erlotinib had a mean survival of 
22.5months compared with only 10.1months 
for those allocated to placebo   
(Provencio, et al., 
2009) 
BATTLE Biomarker-Integrated 
Approaches of Targeted 
Therapy for Lung Cancer 
Elimination 
255 pre-treated NSCLC patients were 
randomised to receive erlotinib, randetanib, or 
sorafenib based on the patients mutation status 
for EGFR and KRAS  
48% disease control at 8 weeks (primary 
endpoint.  
(E. S. Kim et al., 2011) 
BR.21 National Cancer Institute of 
Canada Clinical Trial Group 
Trial 
Randomised phase III trial of erlotinib vs. 
placebo involving 731 patients who had already 
received chemotherapy.  
Erlotinib statistically significant 
improvement in OS and quality of life  
(Cappuzzo, et al., 
2005; Masago, et al., 
2008; Provencio, et al., 
2009) 
PFS = progression free survival, OS = overall survival  
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                                                                                   Appendix III 
The following alignments were a result of comparing the sequences obtained from the Waikato Sequencing Facility and the online 
database (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
EGFR Exon 21 BLAST Alignments 
NSCLC FFPE Specimen 34F3 Forward Sequence 
Query  26   TCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTACTGGTGAAAACACCGCAGCATGT  85 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  24   TCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTACTGGTGAAAACACCGCAGCATGT  83 
 
Query  86   CAAGATCACAGATTTTGGGCTGGCCAAACTGCTGGGTGCGGAAGAGAAAGAATACCATGC  145 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  84   CAAGATCACAGATTTTGGGCTGGCCAAACTGCTGGGTGCGGAAGAGAAAGAATACCATGC  143 
 
Query  146  AGAAGGAGGCAAA  158 
            ||||||||||||| 
Sbjct  144  AGAAGGAGGCAAA  156 
 
NSCLC FFPE Specimen 34F3 Reverse Complement Sequence 
Query  77   GGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTA  136 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCCAGGAACGTA  60 
 
Query  137  CTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAAGTCTCTGGG  196 
            ||||||||||||||||||||||||||||||||||||||||||||||||||| |  ||||| 
Sbjct  61   CTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAACTG-CTGGG  119 
 
Query  197  TGTGGAAGAGAACAGA  212 
            || ||||||||| ||| 
Sbjct  120  TGCGGAAGAGAA-AGA  134 
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EGFR Exon 19 BLAST Alignments 
NSCLC FFPE Specimen 34F3 Forward Sequence 
 
Query  1    ATCTCACAATTGCCAGTTAACGTCTTCCTTCTCTCTCTGTCATAGGGACTCTGGATCCCA  60 
            |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||| 
Sbjct  634  ATCTCACAATTGCCAGTTAACGTCTTCCTTCTCTCTCTGTCATAGG-ACTCTGGATCCCA  692 
 
Query  61   GAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  693  GAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCG  752 
 
Query  121  AAAGCCAACAAGGAAATCCTCGAT  144 
            |||||||||||||||||||||||| 
Sbjct  753  AAAGCCAACAAGGAAATCCTCGAT  776 
 
 
NSCLC FFPE Specimen 34F3 Reverse Complement Sequence 
 
Query  96   GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGA  155 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGA  60 
 
Query  156  GAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTCGATGTG  197 
            |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTCGATGTG  102 
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KRAS Exon 2  BLAST Alignments 
 
NSCLC FFPE Specimen 34F3 Forward Sequence 
 
Query  6    ATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTGACGATACAGCT  65 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  190  ATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTGACGATACAGCT  249 
 
Query  66   AATTCAGAATCATTTTGTGGACGAATATGATCCAACAATAGAGG  109 
            |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  250  AATTCAGAATCATTTTGTGGACGAATATGATCCAACAATAGAGG  293 
 
NSCLC FFPE Specimen 34F3 Forward Sequence 
 
Query  17   CCTCTATTGTTGGATCATATTCGTCCACAAAATGATTCTGAATTAGCTGTATCGTCAAGG  76 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  293  CCTCTATTGTTGGATCATATTCGTCCACAAAATGATTCTGAATTAGCTGTATCGTCAAGG  234 
 
Query  77   CACTCTTGCCTACGCCACCAGCTCCAACTACCACAAGTTTATATTCAGTCATTTTCAGCA  136 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  233  CACTCTTGCCTACGCCACCAGCTCCAACTACCACAAGTTTATATTCAGTCATTTTCAGCA  174 
 
Query  137  GGCCT  141 
            ||||| 
Sbjct  173  GGCCT  169 
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                                                                                    Appendix III 
 
Table 22 Sequencing Data from Standard PCR and direct sequencing. Mutation hotpots in respective exons are in red (KELREA deletion in exon 19, L858R in exon 21 
and codon 12 and 13 SNPs in KRAS) 
Exon 19 Deletions                   
EGFR protein 739 K I P V A I K E L R E A T S P K A N 756 
EGFR gene 2215 AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC 2268 
24A6  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
54A4  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
98F7  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
77B4  AAA ATT CCC GTC GCT ATC AAG _____ ____ _____ _____ GCA ACA TCT CCG AAA GCC AAC  
34F3  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
19A8  ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___  
Exon 21 Mutations                   
EGFR Protein 850 H V K I T D F G L A K L L G 853     
EGFR gene 2538 CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT 2589     
24A6  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
54A4  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
98F7  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
77B4  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
34F3  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
19A8  ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___      
KRAS Exon 2 Mutations                  
KRAS protein 1 M T E Y K L V V V G A G G V G K S A 18 
KRAS gene 1 ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC 54 
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24A6  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
54A4  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
98F7  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
77B4  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
34F3  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
19A8  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
 
 
Table 23 Sequencing Data following COLD-PCR and direct sequencing 
Exon 19 Deletions                   
EGFR protein 739 K I P V A I K E L R E A T S P K A N 756 
EGFR gene 2215 AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC 2268 
24A6  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
54A4  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
98F7  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
77B4  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
34F3  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
19A8  AAA ATT CCC GTC GCT ATC AAG GAA TTA AGA GAA GCA ACA TCT CCG AAA GCC AAC  
Exon 21 Mutations                   
EGFR Protein 850 H V K I T D F G L A K L L G 853     
EGFR gene 2538 CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT 2589     
24A6  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
54A4  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
98F7  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
77B4  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
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34F3  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
19A8  CAT GTC AAG ATC ACA GAT TTT GGG CTG GCC AAA CTG CTG GGT      
KRAS Exon 2 Mutations                   
KRAS protein 1 M T E Y K L V V V G A G G V G K S A 18 
KRAS gene 1 ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC 54 
24A6  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
54A4  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
98F7  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
77B4  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
34F3  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
19A8  ATG ACT GAA TAT AAA CTT GTG GTA GTT GGA GCT GGT GGC GTA GGC AAG AGT GCC  
 
